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 The relationship between diet and health is well established, but renewed interest in 
biologically active food compounds and the examination as to how they exert their effects is 
being powered by the development of nutritional genomics. Nutritional genomics is the 
application of high throughput functional genomic technologies to nutrition research.  
There is overwhelming evidence that diet is a key environmental factor that affects the 
incidence of many chronic diseases. Clearly, a potential for immense benefit through successful 
characterization and exploitation of health-promoting factors in foods exists. The food we eat 
contains thousands of biologically active substances, many of which may have the potential to 
provide substantial health benefits.   
The role of nutrition in cancer depends on how it impacts fundamental cell processes. 
Nutrients and bioactive compounds in food have effects that can inhibit events that lead or 
contribute to cancer development. Several food derived compounds are among the most 
promising chemo-preventive agents which are under evaluation nowadays, although our 
understanding of their mechanisms of action is still quite limited. Nutrigenomics is a novel 
research field that can aid to clarify the impact that nutrients or bioactive compounds may have 
on mechanisms related to cancer development and in the elucidation of our response to diet.  
The following work aims to reveal molecular pathways modulated by walnut polyphenol 
metabolites in a prostate cancer model using a nutrigenomic approach. The main objectives 
were:  I) to identify the polyphenol profile in walnuts, II) to analyze the effect of walnut 
polyphenol metabolites in key signaling pathways in prostate carcinogenesis and development, 
and III) to determine key genes affected by walnut polyphenol incubation in prostate cancer 
cells.  
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1.1.   POLYPHENOLS IN WALNUTS 
Current nutritional approaches reflect a fundamental change in our understanding of 
health. Increasing knowledge regarding the impact of diet on regulation at the genetic and 
molecular levels is redefining the way we consider the role of nutrition, resulting in new dietary 
strategies. Diet not only provides adequate nutrients to meet metabolic requirements, but can 
also contribute to the improvement of human health (Biesalski et al., 2009). Consequently, the 
food industry has been increasingly interested in functional components in food.  
Bioactive compounds are constituents that typically occur in small quantities in foods. 
They are intensively studied to evaluate their effects on health. Many bioactive compounds 
have been discovered and they vary broadly in chemical structure and function. Thus, these 
compounds are usually grouped accordingly to their particular characteristics (Zhang et al., 
2011). Polyphenols are one of the main groups of bioactive compounds found in food and 
beverages (Table 1).  
Table 1. Polyphenols and major dietary sources. 
Phenolic Compound Dietary Source 
Phenolic Acids  
Hydroxycinnamic Acids Blueberries, carrots, cereals, citrus fruits, spinach, tomatoes 
Hydroxybenzoic Acids Blueberries, cereals, cranberries, oilseeds 
Flavonoids  
Anthocyanins Blueberries, cherries, grapes, strawberries 
Chalcones Apples 
Flavanols Apples, blueberries, grapes, onion, lettuce 
Flavanonols Grapes 
Flavanones Citrus fruits 
Flavonols Apples, beans, blueberries, cranberries, lettuce, onion, olive, 
pepper, tomatoes  
Flavones Citrus fruits, celery, parsley, spinach 
Isoflavones Soybeans 
Xanthones Mango 
Tannins  
Condensed Apples, pears, grapes, peaches, plums 
Hydrolysable Walnuts, almonds, pomegranate, raspberries 
Adapted from (Ignat, Volf, & Popa, 2011).  
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 Polyphenols have been widely studied and have been attributed a role in the 
prevention of several diseases such as cancer, diabetes, obesity, in addition to 
neurodegenerative and cardiovascular diseases (Vauzour, Rodriguez-Mateos, Corona, Oruna-
Concha, & Spencer, 2010). Hence, the elucidation of common dietary sources of polyphenols 
remains essential. In particular, walnuts have significantly higher total polyphenol content 
when compared to other nuts common in our diets, such as almonds, hazelnuts, pistachios and 
peanuts (Abe, Lajolo, & Genovese, 2010; Vinson & Cai, 2012). Among the polyphenols 
contained in walnuts, ellagitannins have been reported to be the main phenolic compounds 
found (Fukuda, 2009). 
1.1.1. Ellagitannins 
1.1.1.1 Chemical structure  
Ellagitannins belong to the hydrolysable tannin class of polyphenols (Quideau & 
Feldman, 1996). They can be found mainly in fruits such as, pomegranates, black raspberries, 
raspberries and strawberries, and in nuts, specifically, walnuts and almonds (Landete, 2011). It 
is well documented that the most abundant ellagitannin in walnuts is pedunculagin (C34H26O22) 
(Figure I.1) (Cerdá, Periago, Espín, & Tomás-Barberán, 2005; Regueiro et al., 2014). Ellagitannins 
constitute a complex class of polyphenols characterized by one or more hexahydroxydiphenoyl 
(HHDP) moieties esterified to a polyol usually, glucose or quinic acid (Regueiro et al., 2014). 
These polyphenols have an enormous structural variability due to the different possibilities for 
the linkage of HHDP residues with the sugar moiety, and particularly due to their strong 
tendency to form dimeric and oligomeric derivatives (Niemetz & Gross, 2005). In the hydrolysis 
of ellagitannins with acids or bases, ester bonds are hydrolyzed, and the HHDP group 
spontaneously rearranges into ellagic acid, which has poor water solubility (Garcia-Muñoz & 
Vaillant, 2014).  
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 Figure I.1:  Pedunculagin chemical structure. 
1.1.1.2 Metabolism, absorption and excretion  
The absorption and metabolism of ellagitannins in humans is still quite unknown but 
several animal studies have contributed to their understanding. Several authors have observed 
that ellagitannins are not usually absorbed and must be metabolized prior to absorption 
(Mertens-Talcott, Jilma-Stohlawetz, Rios, Hingorani, & Derendorf, 2006). The absorption of food 
polyphenols is determined primarily by their chemical structure, which depends on factors such 
as the degree of glycosylation, hydroxylation, acylation, conjugation with other phenolics, 
molecular size, degree of polymerization and solubility (Karakaya, 2004). Previous animal 
studies showed that ellagitannins could be hydrolyzed to ellagic acid at the pH found in the 
small intestine and cecum (Daniel et al., 1989; Espín et al., 2007). The presence of free ellagic 
acid in human plasma could be due to its release from the hydrolysis of ellagitannins, enabled 
by physiological pH and/or gut microbiota (Figure I.2).   
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 Figure I.2: Pedunculagin metabolism in gastrointestinal tract. Adapated from (Garcia-
Muñoz & Vaillant, 2014) 
 In a study by Espin et al. (2007) performed on Iberian pigs, the authors observed that 
ellagitannins release ellagic acid under physiological conditions in vivo. Then, ellagic acid is 
gradually metabolized in the intestine, starting in the jejunum, to produce urolithin D, urolithin 
C and finally urolithin A and urolithin B. Urolithin B is mainly produced at the distal parts of the 
intestine. Glucuronides and methyl glucuronides of ellagic acid and particularly urolithin A, C, 
and D derivatives were detected in bile, confirming active enterohepatic circulation. Urolithins 
A and B, and dimethyl-EA glucuronide were also detected in peripheral plasma (Espín et al., 
2007). Some studies have observed that urolithins appear in human systemic circulation within 
a few hours after ellagitannin-rich foodstuff consumption, reaching maximum concentrations 
between 24 h and 48 h post-intake, but they can be present in plasma and urine for up to 72 h, 
in free and conjugated forms (Larrosa, González-Sarrías, García-Conesa, Tomás-Barberán, & 
Espín, 2006; Mertens-Talcott et al., 2006; Seeram, Lee, & Heber, 2004). The presence of ellagic 
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acid metabolites in bile and urine and its absence in intestinal tissues suggest that its 
absorption takes place in the stomach.  
Urolithin A is the main ellagitannin-derived metabolite detected in feces in both pigs 
and humans (Cerdá et al., 2005; Espín et al., 2007), whereas urolithin B is not detected in either 
feces or bile. The large inter-individual variability observed in the production and excretion of 
these metabolites, and the fact that urolithins are excreted independently of the ellagitannins 
consumed, would suggest microbial involvement. Consequently, urolithin production in the 
colon is most likely dependent of the individual’s microbiota (Garcia-Muñoz & Vaillant, 2014).  
Moreover, regarding tissue distribution of urolithins and their conjugates, González-Sarrías et 
al. (2010) found that these molecules reach and enter the human prostate after consumption 
of ellagitannin-rich foods. This was confirmed in a parallel study with rats (González-Sarrías et 
al., 2013). Other tissue disposition studies reveal that urolithins are enriched in prostate, 
intestinal, and colon tissues in mice (Seeram et al., 2007). Thus, urolithins can be considered 
biomarkers of human exposure to dietary EA derivatives (Landete, 2011).  
1.1.1.3 Biological activity 
Ellagitannins, ellagic acid and their derived metabolites possess a wide range of 
biological activities which suggest that they could have beneficial effects on human health 
(Espín, Larrosa, García-Conesa, & Tomás-Barberán, 2013; Landete, 2011). Ellagitannins have 
well-known antioxidant and anti-inflammatory bioactivity, and several studies have assessed 
the potential role of ellagitannins against disease initiation and progression, including cancer, 
cardiovascular and neurodegenerative diseases. The health effects attributed to urolithins, 
based on studies carried out in vitro and in vivo, are numerous and diverse, from anti-malarial 
properties to powerful antioxidant activity (Landete, 2011). Authors have also attributed 
estrogenic and anti-estrogenic activity to urolithins based on their binding affinity to the 
estrogen receptor in MCF-7 cells and the androgen receptor in LNCaP cells, labeling urolithins 
as potential endocrine-disruptive molecules (Larrosa et al., 2006; Sánchez-González, Ciudad, 
Noé, & Izquierdo-Pulido, 2014).   
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The chemo-preventive properties of polyphenols have been widely studied. Polyphenols 
exert their anticancer effects by several mechanisms, such as the reduction of pro-oxidative 
effect of carcinogenic agents (Duthie & Dobson, 1999; Owen et al., 2000), the modulation of 
cancer cell signaling (Corona et al., 2007; Khan & Mukhtar, 2013), cell cycle progression (Corona 
et al., 2009), and promotion of apoptosis (Fabiani et al., 2002; Mantena, Baliga, & Katiyar, 
2006). Polyphenols have also been shown to act on multiple targets in pathways not only 
related to cellular proliferation and death (Fini et al., 2008), but also in inflammation (N. J. Kang, 
Shin, Lee, & Lee, 2011), angiogenesis (Granci, Dupertuis, & Pichard, 2010), and drug and 
radiation resistance (Garg, Buchholz, & Aggarwal, 2005).  
In particular, ellagitannins and ellagic acid seem to exhibit diverse anti-cancer effects, 
and recent research has shown that ellagitannin-rich walnut extracts have dose-dependent 
inhibitory effects on several cancer models (Heber, 2008), both in vitro and in vivo, including 
colon cancer (Qiu et al., 2013), breast cancer cells (Rocha, Wang, Penichet, & Martins-Green, 
2012) and prostate cancer (Bell & Hawthorne, 2008; Naiki-Ito et al., 2015). The effects of walnut 
polyphenols on cancer prevention have been extensively studied showing promising results.  
Both in vitro and in vivo studies that assess the role of ellagitannins in several molecular 
pathways related to cancer initiation, development and progression have been performed.   
1.2. ANALYTICAL METHODS FOR THE DETERMINATION AND QUANTIFICATION OF 
POLYPHENOLS IN FOOD 
In order to assess the biological activity of a determined food source, it is of uttermost 
importance to correctly identify its particular constituents to further evaluate their potential 
bioactive role. To achieve this, the use of accurate and sensitive analytical methods is necessary 
for adequate identification. Analytical signals can be measured in many types of dimensions or 
domains. Typical domains are the time domain (chromatography), the wavelength domain 
(spectrometry), and the space domain (surface analysis) (Schoonjans, Questier, Massart, & 
Borosy, 2000). 
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Chromatography is a tool used in the identification of molecular compounds using the 
time domain (François, Sandra, & Sandra, 2009). It involves a sample dissolved in a mobile 
phase, and the mobile phase is then forced through a stationary phase. The phases are chosen 
so that each component of the sample has differing solubility in each phase. (François et al., 
2009). Techniques such as High Performance Liquid Chromatography (HPLC) and Gas 
Chromatography (GC) use columns packed with stationary phase, through which the mobile 
phase is forced. The sample is transported through the column by continuous addition of 
mobile phase. This process is called elution. The average rate at which an analyte moves 
through the column is determined by the time it spends in the mobile phase. 
Despite a great number of research, the separation and quantification of different 
polyphenols remain difficult (Tsao, 2010). Among the different methods available, HPLC is 
preferred for the separation and quantification of polyphenols in fruits. The type of column 
used to separate phenolics and their glycosides is generally a reverse-phase C18-bonded silica 
column ranging from 100 to 300 mm in length and with an internal diameter of 2–4.6 mm 
(Merken & Beecher, 2000), although occasionally C8 columns are used to separate phenolic 
acids. Columns are maintained from room temperature to 40°C during the analysis but 
thermostated columns give more repeatable elution times and greater resolution, and allow 
the backpressure of the LC column to be reduced at high flow rates (Lamuela-Raventos, 
2014).The use of a binary system is essential for the separation of structurally varied phenolic 
compounds. Gradient elution is usually performed with a solvent A, including an aqueous 
acidified polar solvent or water-containing buffer, and a solvent B, which can be an organic 
solvent such as methanol or acetonitrile, pure or acidified  (Merken & Beecher, 2000; Tsao & 
Deng, 2004).  
Nevertheless, due to the disadvantages in detection limit and sensitivity, HPLC methods 
present limitations especially in complex matrix, such as crude food plant extracts and 
biological fluids. Chromatography–mass spectrometry (LC–MS) techniques are nowadays the 
best analytical approach to study polyphenols in a complex matrix. These techniques are the 
most effective tool for studying the structure of complex polyphenols such as, ellagitannins, 
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procyanidins, anthocyanins, and flavonoids, it also provides experimental evidence for 
structures that were previously only hypothesized (Flamini, 2003). The mass spectrometer 
ionizes the compounds to generate charged molecules and molecule fragments, measuring 
their mass-to-charge ratios (Ignat et al., 2011; Marston & Hostettmann, 2009; Wolfender, 
2009). Different sources can be used for compound ionization: fast atom bombardment (FAB), 
electrospray ionization (ESI), atmospheric pressure chemical ionization (APCI), atmospheric 
pressure photo-ionization (APPI), and matrix-assisted laser desorption ionization (MALDI). The 
detection of the compounds can be performed in positive or negative ion mode, the latter 
being more common in polyphenol analyses (Ignat et al., 2011; Magiera, Baranowska, & Kusa, 
2012; J. Wang & Sporns, 2000). 
Different types of mass analyzers can be used in polyphenol analysis: single quadrupole 
(MS), triple-quadrupole (MS/MS), ion-trap mass spectrometers (MSn), time-of-flight (ToF), 
quadrupole-time-of-flight (QToF), Fourier transform mass spectrometry (FTMS), and Orbitrap-
based hybrid mass spectrometers (LTQ-Orbitrap) (Hooft & Vos, 2012; Meda et al., 2011; 
Mikulic-Petkovsek, Slatnar, Stampar, & Veberic, 2012). 
Quadrupoles consist of four parallel rods connected together, with voltages applied 
between one pair of rods and the other. Ions with a specific mass-to-charge ratio (m/z) will pass 
through the quadrupole when a particular voltage is applied. This enables quadrupoles to filter 
the ions en route to the detector. Triple quadrupole systems are also available, in which the 
first (Q1) and third quadrupole (Q3) work as filters while the second quadruple (Q2) acts as the 
collision cell. The generic mode for screening in MS systems is the full scan, where a mass 
spectrum is acquired every few seconds, thus allowing the identification of the protonated or 
deprotonated molecule and consequently the calculation of the molecular weight of the 
substance. Tandem mass spectrometry enables polyphenols to be detected and quantified in 
complex matrices through MS/MS techniques such as product ion scan, precursor ion scan, and 
neutral loss scan. A product ion scan mass spectrum contains the fragment ions generated by 
the collision of the molecular ion. A precursor ion mass spectrum is obtained by limiting the 
fragment ion to a single ion of interest. Parent ions (molecular ions) are scanned to determine 
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which of them give the target fragment ion. Neutral loss mass spectra show fragment ions with 
a particular loss of mass (Lamuela-Raventos, 2014).  
An ion-trap mass spectrometer (MSn) consists of a chamber with two electrodes and 
two end pieces that trap ions with a series of electromagnetic fields. Once the ions are inside, 
another magnetic field is applied, and only selected ions remain in the chamber. This mass 
analyzer is useful for structural elucidation purposes, performing multiple stage MSn  (Anari, 
Sanchez, Bakhtiar, Franklin, & Baillie, 2004; Wolfender, 2009). The LTQ-Orbitrap, which 
combines an ion-trap analyzer with FTMS, allows MS and MSn analysis with an error of less 
than 2 ppm. LTQ-Orbitrap-MS is a good tool for qualitative analysis, facilitating the structural 
elucidation of unknown compounds (Peterman, Duczak, Kalgutkar, Lame, & Soglia, 2006). 
 Efforts have been previously carried out in order to elucidate the phenolic composition 
of walnuts (Gómez-Caravaca, Verardo, Segura-Carretero, Caboni, & Fernández-Gutiérrez, 
2008), although the specific identities of the major phenolic components of walnuts remains to 
be established. Thus, a strong necessity for the development of an accurate and sensitive 
analytical method to evaluate polyphenolic composition in walnuts exists. In this regard, the 
use of HPLC coupled to MS/MS can provide abundant information for structural elucidation of a 
wide range of compounds. Recently, the combination of Orbitrap technology with LTQ has been 
shown to enable fast, sensitive and reliable detection and identification of small molecules 
regardless of relative ion abundance (Vallverdú-Queralt, 2010).  
1.3. NUTRITIONAL GENOMICS 
The impact of food bioactive compounds on health maintenance and disease prevention 
can be assessed by several methods, but a particularly interesting and novel approach is the 
field of nutritional genomics. (Elliot & Ong, 2002). Nutritional genomics is a relatively recent 
research area in the functional genomics field, which integrates molecular biology, genetics, 
and nutrition. Nutritional genomics is the application of high throughput functional genomic 
technologies to nutrition research (DeBusk, Fogarty, Ordovas, & Kornman, 2005).  
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The term nutritional genomics encompasses two different research areas, 
nutrigenomics and nutrigenetics. It is important to note the difference between both terms 
because although they are closely related, they are not interchangeable due to the nature of 
gene-nutrient interaction they focus on, as seen on Figure I.3. Nutrigenomics focuses on the 
effects of nutrients on genes, proteins, and metabolic processes, whereas nutrigenetics 
involves determining the effect of individual genetic variation, such as polymorphisms, on the 
interaction between diet and disease (Afman & Müller, 2006).  
 
Figure I.3: Nutrient-Gene interaction in Nutritional Genomics. Adapted from (Gillies, 2003). 
In the future, the integration of nutrition and genomics may lead to the use of truly 
personalized diets to prevent or delay the onset of disease and to optimize and maintain human 
health.  
Nutrigenetics aims to understand how the genetic makeup of an individual defines the 
response to diet. If the human population was genetically identical and lived in a constant 
environment, then the response to diet and drugs would be equal; however, this is clearly not 
the case (Mutch, Wahli, & Williamson, 2005). Consequently, nutrigenetics tries to elucidate 
how genetic heterogeneity and nutritional components act jointly in determining an individual’s 
response to food and/or the risk for developing a condition or disease (Mutch et al., 2005). 
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Currently, the majority of nutrigenetics research efforts are focused on single nucleotide 
polymorphisms (SNPs), which are variations with a frequency of more than 1% and they 
account for 90% of all human genetic variation (Wittwer et al., 2011). Nutrigenetics has the 
potential to provide a basis for personalized dietary recommendations based on the individual's 
genetic makeup to prevent common multifactorial disorders decades before their clinical 
manifestation.  
  Novel research in nutrition has focused in the description of how nutritional factors affect 
gene and protein function with a translational output to human health, this concept is known as 
nutrigenomics (Ferguson, 2009). The field of nutrigenomics compromises multiple disciplines and 
includes dietary effects on genome stability (DNA damage at the molecular and chromosome 
level), epigenome alterations (DNA methylation), RNA and micro-RNA expression 
(transcriptomics), protein expression (proteomics) and metabolite changes (metabolomics), all of 
which can be studied independently or in an integrated manner (Kussmann, Raymond, & Affolter, 
2006). In this approach, nutrients, other food components and even whole diets are considered as 
“dietary signals” that are detected by “cellular sensors”. These sensors, that are part of cellular 
signaling cascades, can affect in turn all the processes involved in cell function. Therefore, these 
dietary signals can influence transcription, translation and/or protein expression in one or multiple 
metabolic and regulatory pathways, which ultimately form the phenotype (Ommen & Stierum, 
2002). The pre-requisite of nutrigenomics is the integration of genomics, transcriptomics, 
proteomics and metabolomics to define a “healthy” phenotype. 
  The long-term result of nutrigenomics research is personalized nutrition for health 
maintenance and disease prevention. Transcriptomics serves to put proteomic and metabolomic 
markers into a larger biological perspective and it is suitable for a first “round of discovery” in 
regulatory networks. The analysis of gene expression expands the understanding of regulatory 
networks, it aids in the identification of diagnostic and prognostic biomarkers as well as potential 
targets for medical and nutritional intervention. Moreover, transcriptomic studies have improved 
the understanding of the complex interaction between genetic and environmental factors, such as 
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lifestyle and nutrition (Hocquette, 2005) and have enabled the assessment of nutritional 
interventions at a global gene expression level  (Kussmann et al., 2006). 
Nutrigenomics offers a powerful approach to discover the effects of diet on health. The 
potential of such an approach for nutrition and its role in health management is substantial, 
however, it requires a change on the conception of nutrition. Nutrition can no longer be viewed 
as simply epidemiological studies whose aims are to identify relationships between nutrition 
and chronic disease in genetically uncharacterized populations. Instead, an approach that uses 
complex cell and molecular biology coupled with biochemistry and genetics are required if the 
goals of nutrigenomics are to be accomplished (Mutch et al., 2005). 
1.4 NUTRIGENOMICS AND PROSTATE CANCER 
Prostate cancer is the second most frequently diagnosed cancer and the sixth leading 
cause of cancer death among men. Actually, the highest rates are recorded in North America, 
Oceania, and Northern and Western Europe (American Cancer Society, 2011).  Approximately 1 
in 6 men will be diagnosed with prostate cancer during their lifetime, with over 200,000 men 
diagnosed annually. The conventional treatments for prostate cancer are associated with 
significant morbidity, however, prostate cancer is an attractive target for a preventive approach 
because it generally grows very slowly before symptoms arise and a diagnosis is finally 
established. The long latency period of the disease offers an opportunity for chemo-preventive 
intervention particularly with dietary and lifestyle-based strategies (Venkateswaran & Klotz, 
2010).  
Dietary factors are major elements accounting for the international and interethnic 
differences in the rate of prostate cancer. Epidemiology supports the important role of 
nutrition in prostate cancer prevention (Stacewicz-Sapuntzakis, Borthakur, Burns, & Bowen, 
2008).  In addition, a nutrigenomic approach facilitates the identification of the molecular 
targets of dietary compounds with chemo-preventive activity in prostate cancer. Many agents 
have been evaluated for their chemo-preventive capacities, including soy proteins, lycopene, 
vitamin E, selenium, ω-3 fatty acids, polyphenols including ellagitannins and isoflavones 
(Venkateswaran & Klotz, 2010).  
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Androgens and the androgen-receptor signaling axis are fundamental for the growth 
and development of both normal and cancerous cells in the prostate. Prostate cancer tumor 
growth is initially androgen-dependent. As shown in figure I.4, androgen-dependent signaling 
takes place through dihydrotestosterone stimulation of the androgen receptor.  
 
 
 
Figure I.4.  Androgen receptor signaling in prostate cancer. Adapted from (Lattouf & 
Srinivasan, 2006).  
 
Thus, the mainstay therapy for prostate cancer is androgen ablation, which causes the 
regression of androgen-dependent tumors. Prostate cancer growth depends on the ratio of 
cells proliferating to those dying. Androgens are the main regulator of this ratio by both 
stimulating proliferation and inhibiting apoptosis (Tamburrino et al., 2012). Therefore, prostate 
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cancer depends on a crucial level of androgenic stimulation for growth and survival (Schrijvers, 
2007). However it is well documented that many men fail this therapy and perish of recurrent 
androgen-independent prostate cancer (Schrijvers, 2007).  Androgen-independent prostate 
cancer usually maintains the expression of the AR protein. Some of these tumors initially adapt 
to low androgen environment, while others acquire mutations that allow them to evade the 
normal growth regulation by androgens. It seems that many cases of androgen-independent 
prostate cancer do not develop from a loss of androgen signaling, but rather from the 
acquisition of genetic changes that lead to aberrant activation of the androgen-dependent axis 
through stimulation of multiple signaling pathways  (Figure I.4), including the PI3K and the 
MAPK pathways (Koochekpour, 2010). Therefore, multi-targeted therapies that modulate both 
androgen levels and androgen receptor activation are of crucial necessity.  
 
Both walnut extracts and ellagitannins have been linked to the suppression of prostate 
cancer cell proliferation and the induction of apoptosis (Alshatwi et al., 2012; Naiki-Ito et al., 
2015; Vicinanza, Zhang, Henning, & Heber, 2013). Walnut green husk extracts modulated the 
expression of apoptosis-related genes in a time and dose-dependent manner in PC-3 cells 
(Alshatwi et al., 2012). Furthermore, several authors have observed anti-apoptotic effects of 
ellagitannins in androgen-independent models using prostate cancer cells, such as PC-3 and DU- 
145 (Vicinanza et al., 2013). Another established target in prostate cancer chemoprevention is 
the cytochrome P450 enzyme, CYP1B1. Compounds inhibiting CYP1B1 activity are 
contemplated to exert beneficial effects at three stages of prostate cancer development, that 
is, initiation, progression, and development of drug resistance. Urolithins and specially urolithin 
A, were found to decrease CYP1B1 activity and protein expression (Kasimsetty et al., 2009).   
Animal and human studies on the potential link between walnuts and prostate cancer 
prevention are still limited, but the results seem promising. Reiter et al. (2013) tested whether 
a walnut-enriched diet influenced the growth of prostate cancer xenografts in male nude mice. 
They found that the walnut-enriched diet reduced the number of tumors and the growth of the 
LNCaP xenografts. These authors hypothesized that the walnut-enriched diet forestalled the 
growth of prostate cancer tumors due to an inhibitory effect consequence of the combined 
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actions of several phytochemicals, including the polyphenolic compounds.  In addition, another 
study observed that prostate tumor weight and growth rate were reduced in the TRAMP 
(transgenic adenocarcinoma of mouse prostate) cancer model after a diet rich in walnuts (Davis 
et al., 2012). Like Reiter et al. (2013), the authors stated the beneficial effects of a walnut-
enriched diet probably represent the effects of multiple constituents in whole walnuts and not 
due to specific bioactive compounds.  
Regarding human studies , an intervention study done in sixty-three patients with either 
benign prostate hyperplasia or prostate cancer is worth mentioning. The patients were divided 
into three groups, controls, walnut intake (35g walnuts/day), or pomegranate intake (200mL 
pomegranate juice/day) for 3 days before prostate surgery. The main metabolite detected after 
consumption was urolithin A glucuronide. No apparent changes in the expression of CDKN1A, 
MKi-67 or c-Myc (all related to cancer cell proliferation) were found after consumption of 
walnuts or pomegranate juice. The results from this study demonstrated that conjugates of 
urolithins, specifically glucuronides, and dimethyl ellagic acid can reach and enter the human 
prostate gland upon consumption of ETs-rich sources such as pomegranate juice and walnuts. 
Considering their results and the lack of changes in proliferation markers, these authors 
expressed the need to design better in vitro studies that should focus on the bioactivity and 
exposure time of the actual in vivo metabolites formed upon consumption of ellagitannins.   
(González-Sarrías et al., 2010).   
It is evident that the previously mentioned studies seem to indicate the promising 
effects of walnut polyphenols against prostate cancer and also signal the need to further 
continue the exploration of the interaction between ellagitannins and molecular pathways 
related to cancer development and progression.  
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2. HYPOTHESIS AND OBJECTIVES 
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2.1 HYPOTHESIS 
Walnut polyphenols and their derived metabolites modulate the expression of genes known to 
play an important role in the cancer process. 
2.2 GENERAL OBJECTIVE 
To determine and analyze the changes on gene expression in prostate cancer cells induced by 
walnut polyphenol metabolites using a nutrigenomic approach. 
2.3 SPECIFIC OBJECTIVES 
1. To study the qualitative and quantitative profile of the polyphenols in walnuts. 
1.1. To measure total polyphenol content and antioxidant activity in walnuts. 
1.2. To develop an analytical methodology for the determination of polyphenols in walnuts 
using HPLC-MS. 
2. To identify specific molecular pathways in prostate cancer development and progression 
that could be modulated by walnut polyphenol metabolites (urolithins A and B).  
2.1. To identify the effect of urolithins A and B on androgen dependent signaling, including: 
2.1.1. AR expression and AR-ARE binding. 
2.1.2. PSA expression and transcriptional regulation. 
2.2. To determine the role of urolithins on the induction of apoptosis. 
3. To study the effects of urolithin A on whole genome expression in a prostate cancer model 
using a functional genomics approach. 
3.1. To identify differentially expressed genes upon urolithin A incubation. 
3.2. To determine gene nodes or key genes using Biological Association Networks. 
3.3. To validate the differential expression of gene nodes and further explore the molecular 
pathways where the identified key gene(s) are involved. 
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3. MATERIALS AND METHODS 
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The methodology used for the development of this thesis is described in the articles 
enclosed in the Results section. A detailed description of the most relevant methods and 
materials used in this work is included in this section. 
3.1 MATERIALS 
3.1.1. Walnut polyphenol extract 
A walnut polyphenol extract was used to determine the polyphenolic profile in walnuts. 
In summary 50 g of shelled walnut kernels were used (described below in Methods) to obtain a 
walnut extract. Polyphenol content was determined using the Folin-Ciocalteu method and 
expressed in mg/mL of gallic acid equivalents (Vallverdú-Queralt, 2010). 
3.1.2. Urolithin A and B 
Urolithin A (3,8-dihydroxy-6H-dibenzo[b,d]pyran-6-one ) with 95% purity and Urolithin B 
(UB; 3-dihydroxy-6H-dibenzo[b,d]pyran-6-one) with 98% purity were both synthetized by the 
Department of Organic Chemistry, School of Pharmacy at the University of Barcelona 
(Barcelona, Spain). Urolithin A and B were dissolved in DMSO into 20 mM aliquots. For cellular 
incubation 40 µM of either urolithin A or urolithin B, or a combination composed of 20 µM UA 
and 20 µM UB were used. The final concentration of DMSO in the culture medium was always  
0.5%. 
 
3.1.3. Cell lines 
This work focused on a prostate cancer model, two prostate adenocarcinoma cell lines 
were used. The main cell line used was LNCaP from prostate adenocarcinoma, which expresses 
the androgen receptor and are androgen dependent. In addition, PC-3 prostate 
adenocarcinoma cells (androgen independent and AR-negative) were used as a model to assess 
PSA promoter activity. Both cell lines were routinely grown in Ham’s F-12 medium, 
supplemented with 7% (V/V) fetal bovine serum (FBS, both from GIBCO, Invitrogen, Barcelona, 
Spain), 100U/mL sodium penicillin G and 100mg/L streptomycin, and were maintained at 37˚C 
in a humidified atmosphere containing 5% CO2. Culture expansion upon confluence was 
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performed by trypzinization with 0.05% trypsin and 0.02% EDTA (EDTA was only used in PC3 
cells) in PBS 1x (154mM NaCl, 3.88 mM H2NaPO4, 6.1 mM HNaPO4, pH 7.4) to detach adhered 
cells from culture dishes. The preparation of both medium and trypsin and their sterilization 
with a 0.2μM (pore diameter) filter was performed in our laboratory.  
3.1.4. Plasmids  
Expression vectors were used for the assessment of promoter activity; the following vectors 
were selected for this work: 
 pGL3-Basic (Promega):  basic vector that does not carry an enhancer or promoter 
sequence, but serves as a backbone to attach specific sequences. This vector is resistant 
to ampicillin.  
 pGL3-PSA: luciferase reporter vector carrying 6-kb of the PSA promoter containing three 
androgen response elements. This vector is resistant to ampicillin. This construct was 
provided by Dr Charles Young from the Mayo Clinic, Rochester, MN. 
 WWP-Luc: a p21 promoter construction in front of a luciferase reporter gene, 
streptomycin resistant. WWP-Luc (p21/WAF1 promoter) was obtained from Dr. Bert 
Vogelstein from the Johns Hopkins School of Medicine. 
 
3.2. METHODS 
3.2.1. Walnut polyphenol extract preparation 
Walnut samples were treated in a darkened room with a red safety light to avoid 
oxidation of the polyphenols. Walnuts were manually cracked and shelled, and the seed kernels 
were homogenized with a blender over an ice bath. Immediately afterwards, a 0.50 g aliquot of 
the homogenate was vortexed for 1 min with 4 mL acetone/water (60:40, v/v) and then 
sonicated over an ice bath for 5 min. The extract was centrifuged at 8,000 x g for   minutes at 
   C. The supernatant was collected and the extraction procedure was repeated twice more. 
Supernatants were combined and defatted twice with 4 mL petroleum ether. The acetone-
aqueous phase was then separated by centrifugation at 8,000 × g for   minutes at    C and the 
acetone evaporated under nitrogen flow. The aqueous extract was collected into a 5 mL 
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volumetric flask and filled with 0.1% formic acid in water. An aliquot of the extract was filtered 
by 0.20 µm (pore diameter) for further analysis.  
3.2.2. Total polyphenol determination  
To determine total polyphenol content in walnut polyphenol extract, 20 μL of the 
extract were mixed with 188 μL of Milli-Q water in a 96-well plate (nuncTM, Roskilde, 
Denmark).  Then, 12 μl of Folin-Ciocalteu reagent and 30 μL of sodium carbonate (200 g/l) were 
added. The mixtures were incubated for 1 h at room temperature in the dark. After the reaction 
period, 50 μL of Milli-Q water were added and the absorbance was measured at 765 nm in a 
UV/VIS Thermo Multiskan Spectrum spectrophotometer (Vantaa, Finland). This 
spectrophotometer allowed the absorbance of a 96-well plate to be read in 10 s. Results were 
expressed as mg of gallic acid equivalents (GAE)/100 g walnut sample (dry material) (Vallverdú-
Queralt, 2010).  
3.2.3. Antioxidant capacity 
Antioxidant activity was determined by measuring stable radicals by two methods, 
ABTS+ and DPPH according to the procedure described by Minoggio et al. (2003). To measure 
the antioxidant capacity of walnut polyphenol extract, 5 µL of the extract was mixed with 245 
µL of a methanol solution containing DPPH or ABTS+. After mixing, solutions were kept in the 
dark for 30 minutes and 60 minutes for DPPH and ABTS+ methods respectively, and then 
absorbance was measured at 515 nm in case of DPPH assay and at 734 nm for ABTS+. Inhibition 
percentage in regards to initial absorbance obtained by the ABTS+ or DPPH methanol solution 
was expressed as mmol equivalents of the reference antioxidant (Trolox) per 100 g of sample.  
3.2.4. Liquid chromatography coupled with electrospray ionization hybrid linear trap 
quadrupole-Orbitrap mass spectrometry 
In order to determine the polyphenolic profile in a walnut extract, high performance 
liquid chromatography coupled to a LTQ Orbitrap spectrophotometer was used. These tools 
permit the analysis of walnut polyphenols through the determination of accurate mass 
measurements with errors being below 2 ppm. Liquid chromatography analyses were carried 
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out in an Accela HPLC system from Thermo Fisher Scientific (San Jose, CA, USA) consisting of an 
autosampler, a quaternary pump, a vacuum degasser, a temperature-regulated column, and a 
diode array detector (DAD).  UV/Vis spectra were recorded from 200 to 600 nm, while acquiring 
at a selected wavelength of 280 nm. Chromatographic separation was performed on a 
reversed-phase column Atlantis T3 C18 (100 x 2.1 mm, 3 µm) from Waters (Milford, MA, USA) 
maintained at 25 ºC. Mobile phases A and B were 0.1% formic acid in water and 0.1% formic 
acid in acetonitrile, respectively.  Solvent B increased in linear gradient, as follows:  hold at 
100% A for 1 min, decreased to 92% A over 3 min, decreased to 80% A over 20 min, decreased 
to 70% A over 2 min, decreased to 0% A over 2 min and hold for 6 min, then returned to initial 
conditions over 2 min and re-equilibrated for 5 min. The flow rate and the injection volume 
were set to 350 µL/min and 10 µL, respectively. 
The LC system was coupled to a linear ion trap-Orbitrap mass spectrometer LTQ-
Orbitrap Velos from Thermo Fisher Scientific (San Jose, CA, USA) equipped with an electrospray 
ionization (ESI) source. The ESI source was operated in the negative mode under the following 
specific conditions: source voltage, 3.5 kV; sheath gas, 40 arbitrary units; auxiliary gas, 10 
arbitrary units; sweep gas, 10 arbitrary units; and capillary temperature, 320 °C. Nitrogen (> 
99.98%) was employed as sheath, auxiliary and sweep gas. The scan cycle used a full scan event 
at resolution of 60,000 (at m/z 400) and three data-dependent MS/MS events acquired at a 
resolving power of 30,000. The most intense ions detected in full scan spectrum were selected 
for data-dependent scan. Parent ions were fragmented by high-energy C-trap dissociation 
(HCD) with normalized collision energy of 45% and an activation time of 100 ms. Instrument 
control and data acquisition were performed with Xcalibur 2.0.7 software (Thermo Fisher 
Scientific).  
3.2.5. Microarray data analyses and Biological Association Networks  
Microarrays were performed to obtain a high-throughput functional genomic analysis. 
Gene expression was analyzed by hybridization to Affymetrix Human Genome U219 array plate.  
This platform measures gene expression of more than 36,000 transcripts and variants that 
represent more than 20,000 genes.  
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Genomic analyses were carried out using the GeneSpring GX software v.13 (Agilent 
Technologies). Data was processed by computing the RMA (Robust Multichip Average) 
expression measure in log2 base scale, using a baseline transformation to the median of control 
samples. Differentially expressed genes were obtained by applying a p-value cut-off of less than 
0.05 and a fold change of expression of 2  as described in Selga et al. (Selga, Morales, Noé, 
Peinado, & Ciudad, 2008). Normalized and raw data were submitted to the Gene Expression 
Omnibus database (GEO). The series # GSE65527 was assigned for the data set. 
BANs were constructed with the aid of the Pathway Analysis within the GeneSpring v.13 
(Agilent) as described by Selga et al. (Selga et al., 2009) starting with the list of differentially 
expressed genes after 24 h incubation with UA. NLP Network discovery was performed using an 
advanced analysis with an expanded interactions algorithm to assess relationships among 
entities. The software builds an association network using our differentially expressed data and 
the bibliographic interactions built in the databases. Relevant network associations were 
curated. 
 
3.2.6. Transfection and Luciferase assay 
To assess PSA promoter activity, PC-3 cells (350,000) were plated in 35 mm dishes the 
day before transfection. Medium (2 mL) was renewed before transfection, which was 
performed using FuGENE 6 (Roche, Barcelona, Spain). For each well, transfection reagent was 
incubated for 5 minutes in 100 µL of antibiotic and serum free medium, followed by the 
addition of plasmid DNA and incubated for another 20 min at a ratio of 3:1 (µL of transfection 
reagent : µg of plasmid DNA). One µg of plasmid DNA, either pGL3 basic vector or PSAp, a 6-kb 
PSA promoter construct containing three AREs in front of a luciferase reporter gene, were used 
for transfection. 
Incubation with 40 µM of UA, UB or MIX and 1 nM of DHT was performed 6 hours after 
transfection, and luciferase activity was determined 24 hours after transfection. Cell extracts 
were prepared by lysing cells with 100 µL of Reporter Lysis Buffer (2 mM DTT, 2 mM EDTA, 10% 
glycerol, 1% Triton X_100, 25 mM Tris-Phosphate, pH 7.8). The lysate was centrifuged at 12,000 
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g for 2 min at  ˚C to pellet cell debris and supernatants were transferred to a fresh tube. Fifteen 
µL of the extract were added to 15 µL of the luciferase assay substrate (Promega, Madrid, 
Spain) at room temperature. Luminiscence was measured using the Glomax ™ 20/20 
Luminometer (Promega, Madrid, Spain) and expressed as relative luminescence units (RLU). 
Luciferase results were normalized by total protein concentration in the cell lysates. Protein 
concentration was determined by the Bradford assay (Bio-Rad, Barcelona, Spain) according to 
the manufacturer’s protocol. 
To determine the effect of UA incubation on p21 promoter activity, the same 
experimental approach with minor modifications was performed. In this assay, LNCaP (350,000) 
cells were used and the chosen plasmid was WWP-Luc (previously described).  
3.2.7. Nuclear extracts and Electrophoretic mobility shift assay 
Nuclear extracts were prepared according to the protocol described by Andrews and 
Faller (Andrews & Faller, 1991). Briefly, 500,000 cells were plated and incubated the following 
day with urolithins A, B or MIX and 1 nM DHT.  Cells were collected 24 post-treatment in cold 
PBS. Cells were pelleted and suspended in a cold hypotonic buffer (1.5 mM MgCl2, 10 mM KCl, 
(AppliChem, Barcelona, Spain)  0.5 mM DTT, 0.2 mM PMSF 10 mM HEPES-KOH, pH 8.0 from 
Sigma-Aldrich, Madrid, Spain,). Cells were then allowed to swell for 10 minutes, vortexed and 
pelleted by centrifugation. The resulting pellet was then suspended in a cold high-salt buffer 
(25% glycerol, 420mM NaCl, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.2 mM PMSF, 20 mM 
HEPES-KOH, pH 8.0) for 20 minutes. Cellular debris was removed by centrifugation and the 
supernatant fraction was stored at - 80˚C until further use. 
EMSA assays were then performed using LNCaP nuclear extracts. AR consensus double-
stranded oligonucleotide  ’-CTA GAA GTC TGG TAC AGG GTG TTC TTT TTG CA -3’ (binding site in 
bold) was obtained from Santa Cruz Biotechnology, Heidelberg, Germany (sc-2551). One 
hundred nanograms of the AR consensus sequence was 5’-end-labeled with T4 polynucleotide 
kinase (New England Biolabs, Beverly, MA) and [ᵞ-32P]ATP (3000 Ci/mmol, Perkin Elmer, Madrid, 
Spain) as described in Rodríguez  et al. (2013)(Rodríguez et al., 2013). 
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The radiolabeled probe (20,000 cpm) was incubated in a 20 µl reaction mixture also 
containing 1 µg of Herring Sperm DNA (Invitrogen, Barcelona, Spain) as unspecific competitor, 2 
µg of nuclear extract protein, 5% glycerol, 4 mM MgCI2, 60 mM KCl and 25 mM Tris–HCl, pH 8.0 
(AppliChem, Barcelona, Spain). Samples were resolved by gel electrophoresis (5% 
polyacrylamide, 5% glycerol, 1 mM EDTA and 45 mM Tris-borate, pH 8.0; AppliChem, Barcelona, 
Spain). The gel was dried for 90 minutes, exposed to Europium plates overnight and analyzed 
using a Storm 840 Phosphorimager (Molecular Dynamics, GE Healthcare Life Sciences, 
Barcelona, Spain).  
To determine binding specificity, the radiolabeled ARE probe was competed either with 
3 ng (5-fold) of unlabeled ARE consensus or a mutant ARE oligonucleotide. The mutant AR 
oligonucleotide had two “GT” to “CA” substitutions in the AR binding motif  ’-CTA GAA GTC 
TGC CAC AGG GTC ATC TTT TTG CA -3’ (binding site in bold) (sc-2552, Santa Cruz Biotechnology, 
Heidelberg, Germany). These experiments were performed using NE from LNCaP cells treated 
with 1 nM DHT.  
3.2.8. Apoptosis 
Apoptosis was determined by using two approaches, i) Rhodamine method and ii) 
Caspase 3/7 Glo assay.  To measure apoptosis using Rhodamine,  LNCaP cells (250,000) were 
plated in 35-mm 6-well dishes with 2 ml complete F-12 medium and 24h after, they were 
treated with either 40 µM UA, UB or MIX. Staurosporine (1µM) (Sigma-Aldrich, Madrid, Spain) 
was used as a positive control. Rhodamine (final concentration 5 ng/ml) (Sigma-Aldrich, Madrid, 
Spain) was added for 30 min and the cells were collected, centrifuged at 800 x  g at  ˚C for   
min, and washed once in PBS. The pellet was suspended in 500 ml PBS plus Propidium iodide 
(PI) (final concentration 5 mg/ml) (Sigma-Aldrich, Madrid, Spain). Flow cytometry data were 
analyzed using the Summit v4.3 software. The percentage of Rho-negative, PI negative cells, 
corresponded to the apoptotic population. For the Caspase-Glo 3/7 assay, 10,000 LNCaP cells 
were plated in a 96-well plate in 100µl F12-complete medium. After 24 h, cells were incubated 
with UA for 24h. The following day, 100µl of Caspase-Glo 3/7 reagent was added. After 1 h of 
incubation, luminiscence was measured using a ModulusTM Microplate luminometer (Turner 
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Biosystems, Promega, Madrid, Spain). F12-complete medium and the reagent were considered 
the blank control and untreated cells as background. 
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4.1 ARTICLE I: 
Comprehensive identification of walnut polyphenols by liquid chromatography 
coupled to linear ion trap-Orbitrap mass spectrometry. 
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ABSTRACT 
Introduction: Epidemiologic studies and clinical trials have demonstrated consistent benefits of 
walnut consumption on coronary heart disease risk and other chronic diseases. Walnuts 
(Juglans regia L.) have been described previously as a rich source of polyphenols with a broad 
array of different structures. However, an accurate screening of their complete phenolic profile 
is still lacking. Although efforts have been previously carried out in order to elucidate the 
phenolic composition of walnuts, the specific identities of the major phenolic components of 
walnuts remain to be established. The use of high performance liquid chromatography (HPLC) 
coupled to high-resolution tandem mass spectrometry (HR-MS/MS) can provide abundant 
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Epidemiologic studies and clinical trials have demonstrated consistent beneﬁts of walnut consumption
on coronary heart disease risk and other chronic diseases. Walnuts (Juglans regia L.) have been described
previously as a rich source of polyphenols with a broad array of different structures. However, an accu-
rate screening of its complete phenolic proﬁle is still lacking. In the present work, liquid chromatography
coupled with electrospray ionization hybrid linear trap quadrupole-Orbitrap mass spectrometry
(LC–LTQ-Orbitrap) was applied for a comprehensive identiﬁcation of phenolic compounds in walnuts.
A total of 120 compounds, including hydrolysable and condensed tannins, ﬂavonoids and phenolic
acids were identiﬁed or tentatively identiﬁed on the base of their retention times, accurate mass
measurements and subsequent mass fragmentation data, or by comparing with reference substances
and literature. The peak area of each signal in mass chromatograms was used to provide semiquantitative
information for comparison purposes. The most abundant ions were observed for ellagitannins, ellagic
acid and its derivatives. Furthermore, the high-resolution MS analysis revealed the presence of eight
polyphenols that have never been reported in walnuts: stenophyllanin C, malabathrin A, eucalbanin A,
cornusiin B, heterophylliin E, pterocarinin B, reginin A and alienanin B.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
Walnuts (Juglans regia L.) have been long consumed as a highly
nutritious food in many parts of the world and they are an
important component of the Mediterranean diet (Bulló,
Lamuela-Raventós, & Salas-Salvadó, 2011). Recently, walnuts are
gathering increasing attention for their health-promoting proper-
ties, which have been reported to improve lifestyle-related diseases
such as arteriosclerosis, hypercholesterolemia, hypertriglyceride-
mia cardiovascular disease and diabetes mellitus (Estruch et al.,
2013; Pan, Sun, Manson, Willett, & Hu, 2013; Ros et al., 2004).
Although the health beneﬁts of walnuts are usually attributed to
x-3 fatty acids (Ros et al., 2004) and, to a lesser degree, to the con-
tent of vitamin E (Maguire, O’Sullivan, Galvin, O’Connor, & O’Brien,
2004), walnuts also contain signiﬁcant amounts of other bioactive
compounds such as plant sterols, dietary ﬁber and polyphenols,
that may exert favorable effects on health (Vinson & Cai, 2012). Ithas been established that a handful of walnuts (about 50 g) has sig-
niﬁcantly more total polyphenols than a glass of apple juice
(240 mL), a milk chocolate bar (43 g) or even a glass of red-wine
(150 mL) (Anderson et al., 2001). Moreover, walnut’s total polyphe-
nols were signiﬁcantly higher compared to other nuts common in
our diets (almonds, hazelnuts, pistachios, peanuts, among others)
(Abe, Lajolo, & Genovese, 2010; Vinson & Cai, 2012).
Among the polyphenols found in walnuts, ellagitannins (ETs)
have been reported to be the main phenolic compounds found in
the seed of J. regia L. (Fukuda, Ito, & Yoshida, 2003; Ito, Okuda,
Fukuda, Hatano, & Yoshida, 2007). These compounds, belonging
to the hydrolysable tannin class of polyphenols, are esters of
hexahydroxydiphenic acid (HHDP) and a polyol, usually glucose
or quinic acid (Okuda, Yoshida, Hatano, & Ito, 2009). ETs can occur
as complex polymers reaching high molecular weights, which
makes accurate identiﬁcation difﬁcult.
Although efforts have been previously carried out in order to
elucidate the phenolic composition of walnuts (Fukuda et al.,
2003; Gómez-Caravaca, Verardo, Segura-Carretero, Caboni, &
Fernández-Gutiérrez, 2008; Ito et al., 2007), the speciﬁc identities
of the major phenolic components of walnuts remain to be
established. This is especially noteworthy if we consider the
increasing number of studies dealing with the health beneﬁts of
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quid chromatography (HPLC) coupled to high-resolution tandem
mass spectrometry (HR-MS/MS) can provide abundant information
for structural elucidation of a wide range of compounds. Recently,
the combination of Orbitrap technology with a linear ion trap (LTQ)
has been shown to enable fast, sensitive and reliable detection and
identiﬁcation of small molecules regardless of relative ion
abundance (Vallverdú-Queralt, Jáuregui, Medina-Remón, Andrés-
Lacueva, & Lamuela-Raventós, 2010). This hybrid LTQ-Orbitrap
analysis platform can easily perform multi-stage mass
analyses (MSn) and provide high mass accuracy measurements
for precursor and product ions with fast scan speeds.
The aim of the present work was to provide accurate and com-
prehensive identiﬁcation of the phenolic constituents found in
walnuts by using LC–LTQ-Orbitrap analysis. More than 100 pheno-
lic compounds, including hydrolysable and condensed tannins,
have been tentatively identiﬁed with high mass accuracy, and to
the best of our knowledge, eight of them have never been reported
in walnuts.2. Materials and methods
2.1. Standards, reagents and materials
All solvents were of HPLC grade and all chemicals were of ana-
lytical reagent grade.
Formic acid (98%) and petroleum ether were obtained from
Panreac (Barcelona, Spain). Acetonitrile, acetone and methanol
were purchased from Merck (Darmstadt, Germany). Ultrapure
water was obtained from a Milli-Q Gradient water puriﬁcation sys-
tem (Millipore Bedford, MA, USA). Folin–Ciocalteau (F–C) reagent,
ABTS: 2,20-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid), PBS:
phosphate-buffered saline pH 7.4, Trolox: (±)-6-hydroxy-2,5,7,8-
tetramethylchromane-2-carboxylic acid 97%, sodium carbonate,
and manganese dioxide were purchased from Sigma–Aldrich (St.
Louis, MO, USA); DPPH: 2,2-diphenyl-1-picrylhydrazyl, from Extra-
synthèse (Genay, France);
Ellagic acid (EA), gallic acid, (+)-catechin, ()-epicatechin,
quercetin and chlorogenic acid were obtained from Sigma–Aldrich
(St. Louis, MO, USA). Individual stock solutions of each analyte
and a mixture of them were prepared in methanol. Different
working standard solutions were made by appropriate dilution in
0.1% formic acid in water and then stored in amber glass vials at
20 C.
Walnut samples (J. regia L.) were kindly provided by the Califor-
nia Walnut Commission (Folsom, CA, USA). All samples used were
harvested in the state of California, USA in the year 2012.2.2. Extraction of polyphenols
Walnut samples (n = 5) were treated in a darkened room with a
red safety light to avoid oxidation of the polyphenols. Walnuts
were manually cracked and shelled, and the seed kernels were
homogenized with a blender over an ice bed. Immediately, a
0.5 g aliquot of the homogenate was vortexed for 1 min with
4 mL acetone/water (60:40, v/v) and then sonicated over an ice
bed for 5 min. The extract was centrifuged at 8000g for 5 min at
4 C; the supernatant was collected and the extraction procedure
was repeated twice more. Supernatants were combined and defat-
ted twice with 4 mL petroleum ether. The acetone-aqueous phase
was then separated by centrifugation at 8000g for 5 min at 4 C
and the acetone evaporated under nitrogen ﬂow. The aqueous ex-
tract was collected into a 5-mL volumetric ﬂask and ﬁlled with
0.1% formic acid in water. An aliquot of the extract was ﬁltered
by 0.20 lm and analyzed by LC–LTQ-Orbitrap.462.3. LC/MS analyses
LC analyses were carried out in an Accela HPLC system from
Thermo Fisher Scientiﬁc (San Jose, CA, USA) consisting of an auto-
sampler, a quaternary pump, a vacuum degasser, a thermostated
column compartment and a diode array detector (DAD). UV/Vis
spectra were recorded from 200 to 600 nm, while acquiring at a se-
lected wavelength of 280 nm.
Chromatographic separation was performed on a reversed-
phase column Atlantis T3 C18 (100  2.1 mm, 3 lm) from Waters
(Milford,MA, USA)maintained at 25 C.Mobile phases A and Bwere
respectively, 0.1% formic acid in water and 0.1% formic acid in ace-
tonitrile. The following linear gradient was used: hold at 100%A for
1 min, decreased to 92%A over 3 min, decreased to 80%A
over 20 min, decreased to 70%A over 2 min, decreased to 0%A over
2 min and hold for 6 min, then returned to initial conditions over
2 min and re-equilibrated for 5 min. The ﬂow rate and the injection
volume were set to 350 lL/min and 10 lL, respectively.
The LC system was coupled to a linear ion trap–Orbitrap mass
spectrometer LTQ-Orbitrap Velos from Thermo Fisher Scientiﬁc
(San Jose, CA, USA) equipped with an electrospray ionization (ESI)
source. The ESI source was operated in the negative mode under
the following speciﬁc conditions: source voltage, 3.5 kV; sheath
gas, 40 arbitrary units; auxiliary gas, 10 arbitrary units; sweep
gas, 10 arbitrary units; and capillary temperature, 320 C. Nitrogen
(>99.98%) was employed as sheath, auxiliary and sweep gas. The
scan cycle used a full scan event at resolution of 60,000 (at m/z
400) and three data-dependent MS/MS events acquired at a resolv-
ing power of 30,000. The most intense ions detected in full scan
spectrum were selected for data-dependent scan. Parent ions were
fragmented by high-energy C-trap dissociation (HCD) with normal-
ized collision energy of 45% and an activation time of 100 ms.
Instrument control and data acquisition were performed with
Xcalibur 2.0.7 software (Thermo Fisher Scientiﬁc). An external cal-
ibration for mass accuracy was carried out the day before the anal-
ysis according to the manufacturer’s guidelines.
2.4. Total polyphenols
For the total polyphenols assay (Vallverdú-Queralt,
Medina-Remón, Andres-Lacueva, & Lamuela-Raventos, 2011),
20 lL of the walnut extracts were mixed with 188 lL of Milli-Q
water in a thermo microtiter 96-well plate (nuncTM, Roskilde,
Denmark); afterwards, 12 lL of F–C reagent and 30 lL of sodium
carbonate (200 g/L) were added. The mixtures were incubated for
1 h at room temperature in the dark. After, 50 lL of Milli-Q water
were added and the absorbance was measured at 765 nm in a UV/
VIS Thermo Multiskan Spectrum spectrophotometer (Vantaa,
Finland). Results were expressed as mg of gallic acid equivalents
(GAE)/100 g.
2.5. Antioxidant activity
The antioxidant activity in walnut extracts was measured using
both an ABTS+ radical decolourization assay (Minoggio et al., 2003)
and an DDPH assay (Odriozola-Serrano, Soliva-Fortuny, &
Martin-Belloso, 2008) with minor modiﬁcations (Vallverdú-
Queralt et al., 2011). Brieﬂy, the ABTS + assay consisted in adding
245 lL of ABTS+ solution to 5 lL of Trolox or of walnut extracts.
Then, the solutions were stirred for 30 s and the absorbance was
recorded continuously every 30 s with a UV/VIS Thermo Multiskan
Spectrum spectrophotometer for 1 h. For the DDPH assay, 250 lL
of methanolic DPPH (0.025 g/L) were added to 5 lL of walnut ex-
tracts or of Trolox. Then, the solutions were mixed vigorously
and then kept in darkness for 30 min. Absorption of the samples
was measured on a UV/VIS Thermo Multiskan Spectrum
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analyzed in triplicate and the results were expressed as mmol Trol-
ox equivalent (TE) per 100 g of sample. Methanol blanks were run
in each assay.3. Results and discussion
First of all, total phenols and the antioxidant capacity of the
walnut extracts obtained were determined. The average of the to-
tal polyphenol content of the extracts was 2,464 ± 22 mg GAE/
100 g. These results are in accordance to other studies done with
walnuts in which values ranged from 1,576 to 2,499 mg GAE/
100 g (Abe et al., 2010; Vinson & Cai, 2012). Among nuts, it is quite
well established that walnuts show the highest values of total pol-
yphenol content. On the other hand, the average values for antiox-
idant capacity were 21.4 ± 2.0 mmol TE/100 g and 25.7 ± 2.1 mmol
TE/100 g for the ABTS+ and DPPH assays, respectively. This is in
accordance to other authors (Pellegrini et al., 2006; Vinson & Cai,
2012) who also reported that walnuts showed high scavenging
activities, much higher than other nuts, such as hazelnuts, almonds
or peanuts. Therefore, walnuts seem to consolidate as an important
food source of polyphenols, with a signiﬁcant antioxidant activity.
3.1. Identiﬁcation of phenolic compounds in walnuts
Several mobile phases including methanol–water, methanol–
water with 0.1% formic acid, acetonitrile–water and acetonitrile–
water with 0.1% formic acid were screened in order to improve
the chromatographic separation. Acetonitrile and 0.1% aqueous
formic acid were the most suitable mobile phases. An aqueous-
compatible reversed-phase column Atlantis T3 C18 allowed a suit-
able retention of the most polar compounds under highly aqueous
conditions. The gradient elution was adjusted to achieve a good
separation of major walnut constituents within a short analysis
time. This optimized LC method was found acceptable and ade-
quate for further MS/MS analysis.
Detection was carried out using a LTQ-Orbitrap Velos, consist-
ing of a linear ion trap coupled with an Orbitrap FT mass analyzer,
which gave highly accurate molecular weights and the fragmenta-
tion patterns acquired from multi-stage mass fragmentation for
comprehensive understanding of their chemical structures. The
molecular formulas were selected according to the measured accu-
rate masses and the isotopic patterns, and then searched against
the Dictionary of Natural Products, the Kyoto Encyclopedia of
Genes and Genomes (KEGG) and the Plant Metabolic Network dat-
abases for tentative identiﬁcation. Under these conditions, all pro-
posed molecular formulas were estimated with mass errors below
3.5 ppm. The MS/MS spectra were compared with those of candi-
date compounds found in previous literature, especially when
the presence of the compound was reported in walnuts.
Walnuts were found to contain a highly complex mixture of gal-
lotannins, ellagitannins, ﬂavonoids and phenolic acids; more than
100 individual phenolics were tentatively identiﬁed. Correspond-
ing molecular formulas, their MS/MS fragments, mass measure-
ment errors (Dm) and retention times are shown in Table 1.
Many of these compounds had been previously detected in wal-
nuts. However, the high-resolution MS analyses revealed the pres-
ence of other polyphenols that have never been reported in
walnuts.
3.2. Hydrolysable tannins and related compounds
Major phenolic compounds found in walnut extracts belonged
to the family of ellagitannins (ETs) (Table 1). These compounds
are characterized by their hexahydroxydiphenoyl (HHDP) group,which is released on acid hydrolysis and spontaneously lactonizes
to ellagic acid. ETs, as well as ellagic acid have attracted large
attention due to their high antioxidant activity (Fukuda et al.,
2003; Gil, Tomas-Barberan, Hess-Pierce, Holcroft, & Kader, 2000)
and the health beneﬁts associated with the intake of high ET-
containing foods in the prevention of cardiovascular diseases
(Larrosa, García-Conesa, Espín, & Tomás-Barberán, 2010) and
cancer (Seeram et al., 2007).
Most of identiﬁed ETs in walnuts extracts occurred in several
isomeric forms along the chromatogram (Fig. 1). ETs had two max-
imal UV absorptions at around 220 nm and 270–280 nm, respec-
tively. The ratio of galloyl to HHDP groups esteriﬁed to the
polyol determines the depth of the valley between these absorp-
tion maxima (Hanhineva et al., 2008).
As no standards are available for ETs, the peak area of each sig-
nal in mass chromatograms was used to provide semiquantitative
information for comparison purposes. The most abundant ions
were observed for three isomeric compounds with [M–H] at m/z
783 (peaks 10, 14 and 23), yielding main fragment ions at m/z
301, which corresponds to ellagic acid (M–H-481, loss of HHDP-
glucose) and at m/z 481, which corresponds to deprotonated
HHDP-glucose (M–H-302, loss of HHDP). This fragmentation pat-
tern corresponds to a bis-HHDP-glucose structure, presumably
pedunculagin or casuariin isomers, which have been previously re-
ported as one of the major ETs in walnuts (Cerda, Tomas-Barberan,
& Espin, 2004; Fukuda, 2008, chap. 19).
On the basis of their exact mass and MS/MS data, ﬁve abundant
peaks [M–H] at m/z 951 (peaks 16, 24, 27, 31 and 56) were also
identiﬁed as ellagitannins. All ﬁve peaks lose 44 Da from the [M–
H] ion, consistent with a free carboxyl group in their structure.
MS/MS fragmentation also produced ions at m/z 783 (M–H-168,
loss of gallic acid), m/z 481 (M–H-469, loss of a trisgalloyl group)
and m/z 301, corresponding to ellagic acid. These results suggest
that they consist of a HDDP-glucose and a trigalloyl group such
as valoneoyl, sanguisorboyl, tergalloyl or macaranoyl groups (Oku-
da et al., 2009). Therefore, these ETs were tentatively identiﬁed as
praecoxin A, which has already been detected in walnuts (Fukuda
et al., 2003), including its isomers such as ﬂosin A, platycariin or
platycaryanin B (Tanaka, Kirihara, Nonaka, & Nishioka, 1993).
Five peaks showing signiﬁcant [M–H] signals at m/z 785 were
found (peaks 33, 51, 67, 75 and 87), with fragment ions at m/z 633
(M–H-152, loss a galloyl unit), m/z 483 (M–H-302, loss of HHDP)
and at m/z 301. This fragmentation pattern corresponded to a dig-
alloyl-HHDP-glucose structure, probably tellimagrandin I isomers,
which has been previously identiﬁed in walnuts (Fukuda et al.,
2003).
Three peaks corresponding to [M–H] signals at m/z 481 were
also detected (peaks 1, 2 and 3). Based on their molecular weight
and the presence of an intense product ion at m/z 301, they were
assigned as HHDP-glucose isomers, earlier reported in walnut ex-
tracts (Fukuda, 2008, chap. 19).
Four glansrin C isomers were identiﬁed with [M–H] ions atm/z
933 (peaks 72, 89, 101 and 116) and main MS/MS fragments atm/z
631 (loss of HHDP), m/z 481 (M-452, loss of trigalloyl group), m/z
451 (M-482, loss of HHDP-glucose) andm/z 301. Glansrin C was re-
ported by Fukuda et al. (2003) in walnuts, although other isomers
such as alnusnin B would ﬁt with this fragmentation pattern.
Other monomeric ETs identiﬁed in the present study that have
been previously reported to occur in walnuts are also shown in
Table 1. These compounds are casuarinin/casuarictin isomers
(galloyl-bis-HHDP-glucose), strictinin/isostrictinin isomers (gal-
loyl-HHDP-glucose) and tellimagrandin II/pterocaryanin C isomers.
Another structurally related family of phenolic compounds,
which could be detected in our walnut extracts, was that of ﬂava-
no-ellagitannins hybrids, also referred in literature as complex tan-
nins. The stenophyllanins A and B (Nonaka, Nishimura, & Nishioka,47
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501985), in which an ET (casuarinin or casuariin) is attached via C–C
linkage to the A ring of a (+)-catechin unit, were found with
[M–H] ions at m/z 1207 (peaks 42 and 63). MS/MS spectra of
stenophyllanins A and B yielded ions at m/z 917 (M–H-289, loss
of catechin), m/z 289 (deprotonated catechin) and m/z 301 (depro-
tonated ellagic acid). Stenophyllanins A and B were accompanied
by the structurally related tannin, stenophyllanin C, showing a
[M–H] ion at m/z 1055 (peaks 15 and 20), which corresponded
to the loss of one galloyl group from the molecular mass of
stenophyllanin A or B. Fragment ions at m/z 765 (M–H-289, loss
of catechin), m/z 289 and m/z 301 allowed to assign its identity.
Other ﬂavano-ellagitannin was tentatively identiﬁed as the
epicatechin-based malabathrin A (Okuda et al., 2009) showing a
[M–2H]2 ion at 679 (peak 77), corresponding to a monoisotopic
mass of 1360.1634 Da, and fragment ions at m/z 917 (M–H-441,
loss of epicatechin gallate), m/z 441 (epicatechin gallate), m/z
289 and m/301 (Fig. 2). To our knowledge, this is the ﬁrst time that
the complex tannins stenophyllanin C and malabathrin A have
been identiﬁed in walnuts. Compounds belonging to the same ﬂa-
vano-ellagitannin family, such as accutisim A, have been reported
to exert potential anticancer properties, through DNA topoisomer-
ase II inhibition (Quideau et al., 2003).
Compounds detected at m/z 1085 (peaks 113, 118 and 119)
with fragment ion at m/z 633 corresponding to the HHDP galloyl-
glucose (M-452, loss of trigalloyl group) were assigned to eucalba-
nin A or its isomer cornusiin B. They have been previously found in
leaves and fruits of Eucalyptus species (Hou, Liu, Yang, Lin, & Sun,
2000), but they have never been reported in walnuts. Hetero-
phylliin E and pterocarinin B with [M–H] ions at m/z 907 (peak
32) and 915 (peak 6), respectively, have been also tentatively iden-
tiﬁed here for the ﬁrst time in walnut extracts.
Several dimeric ETs were detected through their [M–2H]2 ions
that were conﬁrmed by the 0.5 Da mass differences between the
isotopic peaks. The selected resolution of 60,000 (at m/z 400)
allowed the determination of the charge state with high accuracy.
Among the identiﬁed ETs dimers, reginin A (dimer of casuarinin
and pendunculagin) and alienanin B (dimer of casuarinin and
stachyurin) isomers showed doubly-charged ions at m/z 858
(peaks 61, 71, 74, 82 and 91) and m/z 926 (peaks 50, 54 and 78),
corresponding to monoisotopic masses of 1718.1440 and
1854.1614 Da, respectively (Fig. 3). Fragmentation of double-
charged ions gave product ions at m/z 933, 783, 481 and 301 for
reginin A isomers, and at m/z 633 and 301 for alienalin B isomers.
As far as we know, this is the ﬁrst report of reginin A and alienalin
B in walnuts.
Although major hydrolysable tannins found in walnuts were
identiﬁed as ellagitannins, important amounts of other gallotan-
nins were also present in the extracts. As known, ellagitannins
are metabolically derived from gallotannins, mainly from pentag-
alloyl-glucose, through C–C oxidative coupling of galloyl groups
(Okuda et al., 2009). The [M–H] ions at m/z 331, 483, 635, 787
and 939 indicated the presence of mono-, di-, tri-, tetra- and pen-
tagalloyl-glucose, respectively. Several isomeric forms of these gal-
loylated esters of glucose with different retention times were
found in our samples (peaks 8, 11, 13, 29, 35, 62, 83, 100, 105
and 114). Fragmentation patterns of polygalloyl-glucoses were
characterized by successive losses of gallic acid (170 Da) and gal-
loyl groups (152 Da). For monogalloyl-glucose (peak 11), MS/MS
fragmentation yielded a predominant ion at m/z 169 after the loss
of the glucosyl moiety (162 Da) and at m/z 271 after cross-ring
fragmentation of glucose (M–H-60) (Meyers, Swiecki, & Mitchell,
2006).
Ellagic acid (EA) and its derivatives were also identiﬁed. The
presence of free EA was conﬁrmed at 23.5 min by a [M–H] ion
at m/z 301 (peak 103), which yielded characteristic MS/MS frag-
ments at m/z 257, 229 and 185 (Mullen, Yokota, Lean, & Crozier,
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Fig. 1. Chromatographic proﬁle obtained at 280 nm for a walnut extract. Peak number identities are displayed in Table 1.
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346 J. Regueiro et al. / Food Chemistry 152 (2014) 340–3482003). In addition to EA, several monoglycosylated EA derivatives
were observed in walnut, such as EA pentoside (m/z 433; peak
95) and EA hexoside (m/z 463; peaks 70 and 73), showing the typ-
ical fragment of EA at m/z 301 in the MS/MS analysis. The antiox-
idant effect of EA, in spite of its rather small size, is quite high in
accordance with the high stability of its free radical. EA exhibits
important health promoting effects via its antioxidant, antiprolif-
erative, chemopreventive, and antiatherogenic activities (Larrosa
et al., 2010).
Valoneic acid dilactone was also identiﬁed, providing a [M–H]
ion at m/z 469 and two main fragments at m/z 425 and 301 due to
the loss of CO2 from the deprotonated molecule and to the ellagic
acid fragment, respectively. Furthermore, two isomers were also
detected with a similar fragmentation pattern, which were tenta-
tively identiﬁed as sanguisorbic acid dilactone and ﬂavogallonic
acid dilactone (Boulekbache-Makhlouf, Meudec, Mazauric, Madani,
& Cheynier, 2013). The latter showed a much lower relative inten-
sity for the ellagic acid fragment, which might be explained by thehigher stability of the C–C linkage between the ellagic acid and the
gallic acid moiety in this compound.3.3. Flavonoids
(+)-Catechin was identiﬁed as the predominant ﬂavan-3-ol with
a [M–H] ion atm/z 289 and MS/MS fragments atm/z 245,m/z 205
and m/z 179. It was in agreement with the results reported by
Gómez-Caravaca et al. (2008) who found catechin in walnuts at
levels from 4.0 to 6.6 mg/kg dry weight.
It was also possible to identify ()-epicatechin (peak 55) that
shares the same [M–H] ion as catechin (peak 34), and
()-epicatechin 3-O-gallate (peak 99), with an [M–H] ion at m/z
441. Oligomeric B-type procyanidins, from dimers up (peaks 25,
28 and 79) to hexamers (peaks 59 and 65), were identiﬁed by their
[M–H] or [M–2H]2 ions and their characteristic MS/MS frag-
ments (Table 1). Previous studies have reported the presence of51
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Fig. 3. Mass spectra showing the doubly-charged ions of reginin A isomer (A) and alienanin B isomer (B).
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although at low concentration levels (Prior & Gu, 2005).
Examination of the chromatograms also revealed the presence
of some quercetin derivatives. The peak detected at m/z 615 with
its fragments at m/z 463 (M–H-152, loss of galloyl group) and m/
z 301.034 (M–H-162, loss of hexosyl group), was tentatively as-
signed to quercetin galloyl-hexoside. Peak at m/z 463 giving the
301.034 fragment, i.e. quercetin after losing a hexose unit
(162 Da) was identiﬁed as a quercetin hexoside, whereas ion [M–
H] at m/z 433 was assigned to quercetin pentoside, also with
MS/MS fragment at m/z 301.034. Trace amounts of quercetin agly-
cone were also detected atm/z 301.034. These ﬂavonols derivatives
have been previously reported in walnuts (Amaral et al., 2004). Fla-
vonol derivatives are valuable phytochemicals consistently associ-
ated with antioxidant and anticarcinogenic activities, and a
relatively longer circulation time in vivo (Nagasawa et al., 2003).3.4. Phenolic acids and related compounds
Phenolic acids are shown to impart antimutagenic, antiglyce-
mic, and antioxidative properties (Scalbert, Manach, Morand,
Rémésy, & Jiménez, 2005). Two peaks were identiﬁed as caffeoyl-
quinic acids (chlorogenic and neochlorogenic acids) based on their
prominent [M–H] ions at m/z 353 and characteristic fragment
ions at m/z 191 (M–H-162, loss of cafeoyl moiety) and 17952(M–H-174, loss of quinoyl moiety). Only chlorogenic acid (3-caf-
feoylquinic acid) could be conﬁrmed by comparing its spectrum
and retention time with those of a standard. Preliminary struc-
ture-activity relationship studies on cinnamic acids and derivatives
have pointed out the importance of the catechol group to their
antiradical efﬁcacy (Silva et al., 2000).
Two more phenolic acids were also identiﬁed since a quasimo-
lecular ion [M–H] atm/z 337 was found for two peaks. Fragmenta-
tion of the ﬁrst one yielded a base peak atm/z 163, corresponding to
the loss of quinic acid radical, which is in accordancewith literature
data found for 3-p-coumaroylquinic acid (Clifford, Johnston, Knight,
& Kuhnert, 2003). The latter gave a base peak at m/z 173, so it was
identiﬁed as 4-p-coumaroylquinic acid. These kind of phenolic
compounds have been previously reported in walnut kernels
(Gómez-Caravaca et al., 2008; Pereira et al., 2007).4. Conclusions
The use of LC coupled with a linear trap quadrupole (LTQ) and a
high-resolution Orbitrap mass analyzer (LC–LTQ-Orbitrap) allowed
us to carry out a comprehensive identiﬁcation of phenolic com-
pounds present in walnuts from J. regia L.
A total of 120 phenolic compounds, including hydrolysable and
condensed tannins, ﬂavonoids and phenolic acids, were identiﬁed
or tentatively characterized based mainly on their accurate mass
348 J. Regueiro et al. / Food Chemistry 152 (2014) 340–348measurement from LTQ-Orbitrap (within 3.5 ppm error), the frag-
ment ions information obtained by MS/MS experiments, as well as
the mass data provided by reference standards and by literature.
Ellagitannins, ellagic acid and its derivatives, coexisted as major
constituent of walnuts, yielding a complex phenolic proﬁle. Eight
of them (stenophyllanin C, malabathrin A, heterophylliin E, ptero-
carinin B, eucalbanin A, cornusiin B, reginin A and alienanin B), as
far as we know, have been identiﬁed for the ﬁrst time in walnuts.
Although signiﬁcant work has been previously reported in the
identiﬁcation of walnut polyphenols, most of it has been carried
out by NMR techniques. Therefore, this research constitutes the
ﬁrst comprehensive identiﬁcation of phenolic compounds in wal-
nuts by LC coupled to high-resolution mass spectrometry. It pro-
vides useful information to further develop new methods for the
reliable quantiﬁcation of these compounds in such a complex ma-
trix, especially for ellagitannins, which levels might be underesti-
mated due to the difﬁculty associated with their analysis.
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ABSTRACT 
Introduction: Prostate cancer is the sixth cause of cancer-related death in men worldwide; 
therefore the identification of new agents that may prevent and/or regulate the progression of 
cancer cell growth is of great interest. Walnuts contain several bioactive compounds shown to 
slow down cancer progression including pedunculagin, a polyphenol that is metabolized by gut 
microbiota to urolithins A and B. An important target in prostate cancer is the androgen 
receptor (AR), which is required for the development of prostate carcinogenesis from early 
prostate intraepithelial neoplasia to organ-confined or locally invasive primary tumors.  This 
study used a prostate cancer cell model to elucidate the effects that urolithins A and B exert 
over the expression and activity of the AR and Prostate Specific Antigen (PSA). 
Materials and methods: LNCaP cells were treated with 40 µM urolithins A and B or a mix  (M) 
of both at several time points.  AR and PSA mRNA and protein levels were determined by RT-
Real Time PCR and Western Blot, respectively.  PSA promoter activity was assessed after 
transient transfection of PC3 cells with a luciferase construct of the PSA-promoter containing 
55
three AREs. Electrophoretic mobility shift assays were performed to evaluate the potential role 
of urolithins on AR–ARE binding.  Apoptosis was measured by flow cytometry after 24 hour 
incubation with either UA or UB or both compounds. The levels of the anti-apoptotic protein 
BCL-2 were determined by Western Blot.  
Results:  A decrease in AR and PSA mRNA and protein levels was observed after treatment 
with urolithins A and B and a mix of both metabolites at every time-point. The inhibition of PSA 
promoter activity after 24 hour incubation with urolithins indicated a possible effect at the 
transcription level on AR-mediated PSA expression. This could be related to a decreased binding 
of AR to the consensus AREs sequence as determined by EMSA. AR and PSA have been shown 
to play an important role in prostate cancer cell viability. Some authors have associated high 
PSA levels with increased levels of the anti-apoptotic protein BCL-2. Hence, we measured the 
effect that UA, UB and M had on apoptosis and BCL-2 levels. An increase in the apoptotic cell 
population was observed upon treatment with UA, UB and M, which correlated with a decrease 
in BCL-2 protein levels.  
Conclusion: Our results suggest that urolithins A and B attenuate the function of the AR by 
repressing its expression. A down-regulation of AR and PSA mRNA and protein levels could 
provoke an interruption of the interaction between PSA and AR, with a proven role in prostate 
cancer development and progression. The modulatory effect of urolithins on the AR receptor 
also causes an apoptotic effect on LNCaP cells.  The aforementioned results indicate a potential 
role of walnuts as a chemo-preventive and/or chemo-therapeutic agent for prostate cancer. 
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Walnut polyphenol metabolites, urolithins A and B,
inhibit the expression of the prostate-speciﬁc
antigen and the androgen receptor in prostate
cancer cells
Claudia Sánchez-González,a Carlos J. Ciudad,b Véronique Noéb and
Maria Izquierdo-Pulido*a,c
Walnuts have been gathering attention for their health-promoting properties. They are rich in poly-
phenols, mainly ellagitannins (ETs) that after consumption are hydrolyzed to release ellagic acid (EA). EA is
further metabolized by microbiota to form urolithins, such as A and B, which are absorbed. ETs, EA and
urolithins have shown to slow the proliferation and growth of diﬀerent types of cancer cells but the
mechanisms remain unclear. We investigate the role of urolithins in the regulatory mechanisms in prostate
cancer, speciﬁcally those related to the androgen receptor (AR), which have been linked to the develop-
ment of this type of cancer. In our study, urolithins down-regulated the mRNA and protein levels of both
prostate speciﬁc antigen (PSA) and AR in LNCaP cells. The luciferase assay performed with a construct
containing three androgen response elements (AREs) showed that urolithins inhibit AR-mediated PSA
expression at the transcriptional level. Electrophoretic mobility shift assays revealed that urolithins
decreased AR binding to its consensus response element. Additionally, urolithins induced apoptosis in
LNCaP cells, and this eﬀect correlated with a decrease in Bcl-2 protein levels. In summary, urolithins
attenuate the function of the AR by repressing its expression, causing a down-regulation of PSA levels and
inducing apoptosis. Our results suggest that a diet rich in ET-containing foods, such as walnuts, could
contribute to the prevention of prostate cancer.
1. Introduction
Prostate cancer is the second most frequently diagnosed
cancer and the sixth leading cause of cancer death among
men. Generally, the highest rates are recorded in North
America, Oceania, and Northern and Western Europe.1 Epide-
miology supports the important role of nutrition in prostate
cancer prevention.2 A number of protective compounds have
been identified in the diet, including selenium, sulforane
from cruciferous, carotenoids, and polyphenols. These food
phytochemicals may aﬀect the biological process of cancer
development via diﬀerent mechanisms. In vitro and in vivo
evidence has pointed out that phytochemicals aﬀect a broad
range of intracellular molecular targets.3–7 In particular, poly-
phenols may exert anticancer eﬀects by several mechanisms
such as reducing the pro-oxidative eﬀect of carcinogenic
agents,8,9 modulation of cancer cell signaling,10,11 cell cycle
progression,12,13 promotion of apoptosis,14,15 and modulation
of enzymatic activities.16 Regarding prostate cancer pro-
gression, a recent clinical trial assessed the eﬀect of a poly-
phenol-blend dietary supplement over prostate-specific antigen
(PSA) levels in men with localized prostate carcinoma; this
study found a significant favorable eﬀect on the percentage
rise in PSA levels, an important indicator of prostate cancer
progression.17 Polyphenols have also been shown to act on
multiple targets in pathways not only related to cancer pro-
gression, cellular proliferation and death,18 but also in inflam-
mation,19 angiogenesis,20 and drug and radiation resistance.21
Walnuts ( Juglans regia L.) have been gathering increasing
attention for their health-promoting properties, which have
been reported to improve lifestyle-related diseases such as
arteriosclerosis, hypercholesterolemia, hypertriglyceridemia,
cardiovascular disease, diabetes, and cancer.22–24 Walnuts are
rich in bioactive polyphenols (total contents ranging from
1575 mg to 2500 mg per 100 g) and they represent, on a
serving size basis, the seventh largest source of total poly-
phenols among common foods and beverages.25 The most
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abundant polyphenols in walnuts are ellagitannins (ETs),
mainly pedunculagin.26 ETs are tannins that release ellagic
acid (EA) upon hydrolysis, which are further metabolized by
gut flora to form urolithins, mainly urolithins A and B.27
These urolithins circulate in blood and can reach many of the
target organs where the eﬀects of ellagitannins are noted.27,28
Although the occurrence of ETs and EA in the bloodstream is
almost negligible, urolithins can reach a concentration at
micromolar levels in plasma,29 their maximum concentration
is reached 24 to 48 hours after consumption of ET-rich foods,
although urolithins can be found in plasma and urine up to
72 hours after consumption in both free and conjugated
forms;27 urolithins and their conjugates have also been found
in the human prostate after walnut and pomegranate juice
consumption.30 Like other polyphenols, ETs, EA and their
derived metabolites possess a wide range of biological activi-
ties which suggest that they could have beneficial eﬀects on
human health.31 Moreover, ETs and EA seem to exhibit anti-
cancer properties in vitro and in vivo. Recent research in vitro
has shown that walnut extracts have dose-dependent inhibitory
eﬀects on colon cancer cell growth32 and it has been observed
that walnuts delay the growth rate of breast cancer cells33 and
prostate cancer cells30 implanted in mice. ET-rich herbal
extracts have been shown to inhibit LNCaP cell proliferation
and reduce PSA secretion.34 Other authors have also attributed
estrogenic and anti-estrogenic activity to urolithins based on
their binding aﬃnity to the estrogen receptor in MCF-7 cells,
labeling urolithins as potential endocrine-disruptive molecules.29
Prostate-specific antigen is a well-known prostate tumor
marker, expressed at a high level in the luminal epithelial cells
of the prostate and is absent or expressed at very low levels in
other tissues.35 However recent data suggest that PSA is not
only a biomarker, but that it also has a biological role in the
development and progression of prostate cancer, since it is
involved in tumor growth, invasion and metastasis.36 PSA is
encoded by the KLK3 gene and its expression is tightly con-
trolled by androgen through the action of the androgen recep-
tor (AR).37 Upon binding to androgen, AR translocates into the
nucleus and binds to the androgen response elements (AREs)
on the PSA promoter, interacting with other transcription
factors and activating PSA gene transcription.38 The expression
of PSA in prostate cancer generally reflects the transcriptional
activity of AR, but additional factors regulating the PSA promo-
ter have also been identified.39–41
Considering all of the above, we hypothesized that the
main walnut polyphenol metabolites, urolithins A and B,
could exert a role over regulatory mechanisms in prostate
cancer, specifically those related to the androgen receptor,
which have been linked to the development and progression of
this type of cancer. To this purpose, and using a prostate
cancer cell model (LNCaP cells), we investigated the eﬀects of
urolithins A and B on the gene expression of PSA and AR and
their protein expression. We also assayed the ability of those
compounds to modify the PSA promoter activity and to bind
AR. In addition, the eﬀect of both urolithins on apoptosis was
also explored.
2. Experimental
2.1 Materials and chemicals
Urolithin A (UA; 3,8-dihydroxy-6H-dibenzo[b,d]pyran-6-one,
95% purity) and urolithin B (UB; 3-dihydroxy-6H-dibenzo[b,d]-
pyran-6-one, 98% purity) were synthesized by the Department
of Organic Chemistry, School of Pharmacy at the University of
Barcelona (Barcelona, Spain). Urolithins and dehydrotesto-
sterone (DHT) (Sigma-Aldrich, Madrid, Spain) were suspended
in DMSO.
2.2 Cell culture
LNCaP (androgen responsive) and PC3 (androgen indepen-
dent) human prostate adenocarcinoma cell lines were routinely
grown in Ham’s F-12 medium, supplemented with 7% (v/v)
fetal bovine serum (FBS, both from GIBCO, Invitrogen, Barce-
lona, Spain), sodium penicillin G and streptomycin, and were
maintained at 37 °C under a humidified atmosphere contain-
ing 5% CO2. 250 000–500 000 cells were incubated with 40 μM
of either urolithin A or urolithin B, or a combination com-
posed of 20 μM UA and 20 μM UB (named MIX). This concen-
tration was chosen because it can be found in plasma after
consumption of ET-rich foods,26–28 and it is within the range
used to assay the biological activity of urolithins.42,43
In addition, this concentration was not cytotoxic (data not
shown). Incubations were also performed, depending upon the
experiment, with 1 nM of DHT. The final concentration of
DMSO in the culture medium was always ≤0.5%.
2.3 RT-real time PCR
Total RNA was extracted from LNCaP using the Trizol reagent
(Life Technologies, Madrid, Spain) in accordance with the
manufacturer’s instructions. Complementary DNA (cDNA) was
synthesized as described by Oleaga et al. (2013).44 RNA concen-
tration and purity was checked using a Nanodrop spectro-
photometer system (ND-1000 3·3 Nanodrop Technologies,
Wilmington, DE, USA). mRNA levels were determined with Ste-
pOnePlus™ real-time PCR systems (Applied Biosystems, Barce-
lona, Spain) using 3 μL of cDNA and Taqman probes (Applied
Biosystems, Barcelona, Spain), for KLK3 (Hs02576345) and AR
(Hs00171172) genes and APRT (Hs00975725) as an endogenous
control. Changes in gene expression were calculated using the
quantitative ΔΔCt method and normalized against APRT in
each sample.
2.4 Western blot
LNCaP cells (350 000) were plated on 35 mm dishes and
treated the day after with the diﬀerent compounds. Twenty-
four hours after incubation cells were collected and centri-
fuged for 5 min at 800g at 4 °C. The cell pellets were sus-
pended in 200 μL of lysis buﬀer (0.5 M NaCl, 1.5 mM MgCl2,
1 mM EGTA, 10% glycerol 1% Triton x_100, 50 mM HEPES,
pH 7.9 all from Applichem, Barcelona, Spain), and 10 μL pro-
tease inhibitor cocktail (from Sigma-Aldrich, Madrid, Spain).
The cell lysate was kept on ice for 60 min vortexing every
15 min. Cellular debris was removed by centrifugation at
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15 000g at 4 °C for 10 min. A 5 μL aliquot of the extract was
used to determine the protein concentration using the Brad-
ford assay (Bio-Rad, Barcelona, Spain).
Whole cell extracts (100 μg) were resolved in 12% SDS-poly-
acrylamide gels and transferred to PVDF membranes (Immobi-
lon P, Millipore, Madrid, Spain) using a semidry electroblotter.
Membranes were probed overnight at 4 °C with primary anti-
bodies against AR (1 : 200 dilution; sc-816 from Santa-Cruz Bio-
technology Inc., Heidelberg, Germany), PSA (1 : 300 dilution;
A0562 from Dako, Denmark) or Bcl-2 (1 : 200 dilution; sc-492
from Santa-Cruz Biotechnology Inc., Heidelberg, Germany).
Signals were detected by secondary horseradish peroxidase-
conjugated antibody, either anti-rabbit (1 : 2500; Dako,
Denmark) or anti-mouse (1 : 2500 dilution, sc-2005 Santa Cruz
Biotechnology Inc., Heidelberg, Germany) and enhanced che-
miluminescence using the ECL™ Prime Western blotting
detection reagent, as recommended by the manufacturer (GE
Healthcare, Barcelona, Spain). Chemiluminescence was
detected with ImageQuant LAS 4000 Mini technology (GE
Healthcare, Barcelona, Spain). Normalization of the blots was
performed by incubation with an antibody against tubulin
(1 : 800 dilution, sc-5286 from Santa-Cruz Biotechnology Inc.,
Heidelberg, Germany).
2.5 Transfection and luciferase assay
PC3 cells (350 000) were plated in 35 mm dishes the day before
transfection. The medium (2 ml) was renewed before transfec-
tion, which was performed using FuGENE 6 (Roche, Barcelona,
Spain). For each well, the transfection reagent was incubated
for 5 minutes in 100 μL of antibiotic and serum free medium,
followed by the addition of plasmid DNA and incubated for
another 20 min at a ratio of 3 : 1 (μL of transfection reagent : μg
of plasmid DNA). One μg of plasmid DNA, either pGL3 basic
vector or PSAp, a 6 kb PSA promoter construct containing
three AREs in front of a luciferase reporter gene were used for
transfection.
Incubation with 40 μM of UA, UB or MIX and 1 nM of DHT
was performed 6 hours after transfection, and the luciferase
activity was determined 24 hours after transfection. Cell
extracts were prepared by lysing cells with 100 μL of reporter
lysis buﬀer (2 mM DTT, 2 mM EDTA, 10% glycerol, 1% Triton
X_100, 25 mM Tris-phosphate, pH 7.8). The lysate was centri-
fuged at 12 000g for 2 min at 4 °C to pellet cell debris and
supernatants were transferred to a fresh tube. Fifteen μL of the
extract were added to 15 μL of the luciferase assay substrate
(Promega, Madrid, Spain) at room temperature. Luminescence
was measured using the Glomax™ 20/20 luminometer
(Promega, Madrid, Spain) and expressed as relative lumine-
scence units (RLU). Luciferase results were normalized by the
total protein concentration in the cell lysates. Protein concen-
tration was determined by the Bradford assay (Bio-Rad, Barce-
lona, Spain) according to the manufacturer’s protocol.
2.6 Nuclear extracts
Nuclear extracts were prepared according to the protocol
described by Andrews and Faller (1991).45 Briefly, 500 000 cells
were plated and incubated the following day with urolithins A,
B or MIX and 1 nM DHT. Cells were collected in cold PBS after
being treated for 24 hours. Cells were pelleted and suspended
in a cold hypotonic buﬀer (1.5 mM MgCl2, 10 mM KCl (Appli-
Chem, Barcelona, Spain), 0.5 mM DTT, 0.2 mM PMSF, 10 mM
HEPES-KOH, pH 8.0 from Sigma-Aldrich, Madrid, Spain). Cells
were then allowed to swell for 10 minutes, vortexed and pel-
leted by centrifugation. The resulting pellet was then sus-
pended in a cold high-salt buﬀer (25% glycerol, 420 mM NaCl,
1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.2 mM PMSF,
20 mM HEPES-KOH, pH 8.0) for 20 minutes. Cellular debris
was removed by centrifugation and the supernatant fraction
was stored at −80 °C until further use.
2.7 Electrophoretic mobility shift assay
EMSA assay was performed using LNCaP nuclear extracts pre-
pared as previously described. AR consensus double-stranded
oligonucleotide 5′-CTA GAA GTC TGG TAC AGG GTG TTC TTT
TTG CA-3′ (binding site in bold) was obtained from Santa Cruz
Biotechnology, Heidelberg, Germany (sc-2551). One hundred
nanograms of the AR consensus sequence was 5′-end-labeled
with T4 polynucleotide kinase (New England Biolabs, Beverly,
MA) and [γ-32P]ATP (3000 Ci mmol−1, Perkin Elmer, Madrid,
Spain) as described by Rodríguez et al. (2013).46
The radiolabeled probe (20 000 cpm) was incubated in a
20 μL reaction mixture also containing 1 μg of Herring sperm
DNA (Invitrogen, Barcelona, Spain) as an unspecific competi-
tor, 2 μg of nuclear extract protein, 5% glycerol, 4 mM MgCI2,
60 mM KCl and 25 mM Tris-HCl, pH 8.0 (AppliChem, Barce-
lona, Spain). Samples were resolved by gel electrophoresis (5%
polyacrylamide, 5% glycerol, 1 mM EDTA and 45 mM Tris-
borate, pH 8.0; AppliChem, Barcelona, Spain). The gel was
dried for 90 minutes, exposed to europium plates overnight
and analyzed using a Storm 840 Phosphorimager (Molecular
Dynamics, GE Healthcare Life Sciences, Barcelona, Spain).
To determine the binding specificity, the radiolabeled ARE
probe was competed either with 3 ng (5-fold) of unlabeled ARE
consensus or a mutant ARE oligonucleotide. The mutant AR
oligonucleotide had two “GT” to “CA” substitutions in the AR
binding motif 5′-CTA GAA GTC TGC CAC AGG GTC ATC TTT
TTG CA-3′ (binding site in bold) (sc-2552, Santa Cruz
Biotechnology, Heidelberg, Germany). These experiments
were performed using NE from LNCaP cells treated with 1 nM
DHT.
2.8 Apoptosis
Apoptosis was determined by the rhodamine method. LNCaP
cells (250 000) were plated in 35 mm dishes with 2 ml com-
plete F-12 medium and after 24 h, they were treated with
40 μM UA, UB or MIX. Staurosporine (1 μM) (Sigma-Aldrich,
Madrid, Spain) was used as a positive control. Rhodamine
(final concentration 5 ng ml−1) (Sigma-Aldrich, Madrid, Spain)
was added for 30 min and the cells were collected, centrifuged
at 800g at 4 °C for 5 min, and washed once with PBS. The
pellet was suspended in 500 ml PBS plus propidium iodide
(PI) (final concentration 5 mg ml−1) (Sigma-Aldrich, Madrid,
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Spain). Flow cytometry data were analyzed using the Summit
v4.3 software. The percentage of Rho-negative, PI negative cells
corresponds to the apoptotic population.
2.9 Statistical analyses
All data are reported as mean ± SE and are representative of at
least three independent experiments. Data were analyzed
using one-way ANOVA followed by the Bonferroni post hoc
multiple range test using the SPSS software v.21. The diﬀer-
ence between groups was considered statistically significant at
p < 0.05.
3. Results
3.1 Urolithins A and B decrease PSA mRNA and protein
levels in LNCaP cells
Taking into account the role of prostate specific antigen in
prostate cancer, we analyzed the eﬀect of urolithins on PSA
mRNA expression. LNCaP cells were incubated with urolithins
during diﬀerent time periods (12, 24, and 48 h). Total RNA was
extracted and PSA expression was analyzed by RT-real time
PCR (Fig. 1A). On average, urolithins induced the major
decrease in PSA mRNA levels after 24 hours; urolithin A pro-
voked an 85% reduction, a similar eﬀect was observed after
incubation with MIX at the same time point, while UB exerted
a 50% inhibition. To examine whether the eﬀects observed at
the mRNA level were translated into the protein, we performed
Western blot analyses in LNCaP cells after 24 hour incubation
with urolithins. As shown in Fig. 1B, cells incubated with UA
exhibited a 63% decrease in PSA protein levels compared
to the untreated control, followed by cells treated with MIX
or UB.
3.2 Urolithins A and B decrease AR mRNA and protein
expression
To determine whether urolithins were able to modulate AR
mRNA expression, LNCaP cells were incubated for several time
periods, between 9 and 24 hours; total RNA was extracted and
AR expression was analyzed by RT-real time PCR. A decrease in
AR mRNA levels was observed at every time point (Fig. 2A).
The major decrease was observed after the incubation with UA
and MIX, obtaining on average a reduction of 60% for both
9 and 12 hours. Androgen receptor protein levels were also
determined in LNCaP cells treated with urolithins, inducing a
decrease between 50% and 60% (Fig. 2B).
3.3 Urolithins A and B inhibit the PSA promoter activity
To assess whether urolithins aﬀected the transcriptional acti-
vation of PSA, transient transfections in PC3 cells using a luci-
ferase reporter vector carrying 6 kb of the PSA promoter were
performed.47 PC3 cells were chosen because they are PSA nega-
tive and although they are considered AR-negative they do
express low AR mRNA and protein levels48 in addition to retain-
ing co-regulators necessary for AR activity in prostate tumor pro-
gression.49 Therefore, changes in PSA promoter activity would
be accurately reflected after incubation with urolithins and/or
DHT in these reporter assays. Six hours after transfection with
the reporter vector, cells were incubated with urolithins, either
in the absence or in the presence of DHT. As expected, treatment
with 1 nM DHT increased the luciferase activity by 83% com-
pared to cells incubated in the absence of DHT, which exhibited
similar activity to the basic pGL3 vector (Fig. 3). DHT-incubated
cells treated with UA, UB or MIX showed a reduction in lucifer-
ase activity. UA-incubated cells showed a slightly higher inhi-
bition in luciferase activity than UB and MIX when compared to
the DHT-induced promoter, although this was not statistically
Fig. 1 (A) PSA mRNA levels determined by real time RT-PCR. Bars represent PSA mRNA levels in LNCaP cells either control (0.10% of DMSO) or
incubated with UA, UB or MIX. The diﬀerent incubation conditions are indicated in the ﬁgure. Results are expressed in fold changes compared to the
untreated cells and normalized using APRT as an endogenous control. They are the mean ± SE of 3 diﬀerent experiments. ***p < 0.001. (B) Determi-
nation of PSA protein levels by Western blotting. Bars represent PSA protein levels in LNCaP cells either control (0.10% of DMSO) or incubated with
UA, UB or MIX. Results are expressed in fold changes compared to the untreated cells and represent the mean ± SE of 3 diﬀerent experiments. ***p
< 0.001.
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significant (Fig. 3). These results indicated a repression of DHT-
induced PSA promoter activation by urolithins. Cells incubated
only with UA, UB or MIX exhibited basal luciferase activity,
similar to the activity observed for pGL3 and PSAp in the
absence of DHT (inactive PSAp, data not shown).
3.4 PSA expression correlates with the binding of nuclear
extracts to an ARE
The regulation of PSA by androgens takes place through
the ARE sequences in its promoter region.38 The eﬀect of
Fig. 2 (A) AR mRNA levels determined by real time RT-PCR. Incubation conditions are the same as described in Fig. 1A. Results are expressed in fold
changes compared to the untreated cells and normalized using APRT as an endogenous control. They are the mean ± SE of 3 diﬀerent experiments.
***p < 0.001. (B) Determination of AR protein levels by Western blotting. Results are expressed in fold changes compared to the untreated cells and
represent the mean ± SE of 3 diﬀerent experiments. ***p < 0.001.
Fig. 3 PSA promoter activity in PC3 cells. Cells were transfected with a
luciferase reporter vector carrying 6 kb of the PSA promoter, and 6 h
later they were treated with UA, UB and MIX in the presence or absence
of 1 nM DHT. Results are expressed as luciferase relative units/total
protein compared to control. They are the mean ± SE of 3 diﬀerent
experiments. ***p < 0.001. N.S., not signiﬁcant. Fig. 4 (A) Eﬀect of urolithins on AR binding to nuclear proteins. EMSA
was performed using the AR consensus sequence as a probe and
nuclear extracts from LNCaP cells. First lane corresponds to the probe
alone. Nuclear extracts were either control or treated cells with 1 nM
DHT and 40 μM of UA, UB or MIX for 24 hours. ***p < 0.001. N.S., not
signiﬁcant. (B) Competition assays. The binding of untreated LNCaP
nuclear extracts to the AR consensus sequence was competed with the
addition of either 3 ng (5-fold excess) of unlabeled AR or unlabeled
mutated AR in the binding reaction.
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urolithins on ARE binding to nuclear proteins was determined
using electrophoretic mobility shift assays (EMSAs). EMSAs
were performed using an ARE consensus sequence as the
probe and nuclear extracts from untreated (control) and
treated LNCaP cells. Cells were incubated with 1 nM DHT and
urolithins for 24 hours. As shown in Fig. 4A, the interaction of
nuclear extracts from control cells with the radiolabelled probe
originated a shifted band, the intensity of which was clearly
decreased upon incubation with UA, UB or MIX. The highest
reduction was seen after UA and MIX incubation (Fig. 4A),
with an 85% decrease in band intensity, followed by UB.
To assess the binding specificity, 3 ng of unlabeled consen-
sus ARE (corresponding to a 5-fold excess compared to the
probe) or unlabeled mutated AR were added to the binding
reaction. As shown in Fig. 4B, a 56% reduction in band inten-
sity was observed when the binding to the ARE labeled probe
was competed with the unlabeled probe, whereas the compe-
tition with the unlabeled mutated AR did not aﬀect the inten-
sity of the shifted band.
3.5 Urolithins A and B induce apoptosis and a decrease of
Bcl-2 protein levels in LNCaP cells
We examined the eﬀect of urolithins on apoptosis using the
rhodamine method. Following incubation of LNCaP cells with
UA, UB and MIX for 24 hours, the percentage of apoptotic cells
increased compared with the control (0.20% DMSO). A 14%
increase in apoptotic cell population was observed after incu-
bation with UA, whereas UB and MIX caused a 7% increase,
although this diﬀerence was not statistically significant
(Fig. 5A–5C). Both in vitro and in vivo studies have established
that Bcl-2 expression confers anti-apoptotic activity in prostate
cancer and its overexpression is linked to progression into
advanced prostate cancer.50 Bcl-2 overexpression has also been
correlated with high PSA levels in prostate cancer.36 Hence,
Bcl-2 protein levels were measured after urolithin incubation.
UA, UB and MIX induced a decrease in Bcl-2 protein levels
after 24 hour treatment (Fig. 5D).
4. Discussion
The main objective of our study was to determine the potential
role of the major polyphenol metabolites in walnuts, uro-
lithins, in the modulation of the prostate-specific antigen and
the androgen receptor in prostate cancer cells. A great number
of dietary components such as lycopene, vitamin E, selenium,
isoflavones and polyphenols potentially aﬀect a range of carci-
nogenic pathways in the prostate, including androgen meta-
bolism, cell cycle processes and apoptosis, maintenance of
mitochondrial membrane potentials, insulin-like growth factor
Fig. 5 Apoptosis determined by ﬂow cytometry. (A) Representative ﬂow cytometer histograms displaying the cell population in the untreated
control sample (0.12% DMSO) and (B) in cells incubated with 40 μM UA. (C) Percentage of apoptotic cells determined by ﬂow cytometry. Bars rep-
resent LNCaP cells either untreated control (0.12% of DMSO), or incubated with UA, UB or MIX (40 μM) after 24 hour of exposure. Results represent
the mean ± SE of 3 diﬀerent experiments. *p < 0.05. (D) Bcl-2 protein levels in cells incubated with UA, UB or MIX for 24 hours. ***p < 0.001.
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(IGF)-Akt signaling, and response to oxidative stress.51
Although, these dietary components have been assessed for
their chemo-preventive capacities, there are a limited number
of studies focusing on the role that walnut polyphenols have in
the prevention of prostate cancer, especially those addressed
to elucidate the molecular mechanisms involved. As an
example, the anticancer activity for urolithins A, B, C, and D
through the inhibition of CYP1B152 was reported in human
prostate carcinoma 22Rv1 cells, while pedunculagin,30 ellagic
acid42 and extracts from the green husk of walnuts53 showed
an anti-proliferative and apoptotic eﬀect on LNCaP cells. Other
authors have also observed that urolithins localized to the
mouse prostate gland and inhibited the growth of both andro-
gen-dependent and androgen-independent prostate cancer cell
lines.54
In our study, there was a clear repression of PSA transcrip-
tion by urolithins A and B, as well as a decrease in PSA protein
levels. The aforementioned decrease in PSA levels upon treat-
ment with urolithins correlated with the down-regulation of
the androgen receptor. The decrease in PSA and AR levels after
incubation with urolithins is in agreement with the eﬀects
reported for other phenolic compounds, such as epigallocate-
chin gallate (EGCG), grape seed procyanidins or caﬀeic acid.
PSA and AR play a pivotal role in prostate cancer development
and progression and a potential cross-talk between these two
genes has been postulated by several authors.55,56 In a recent
study, Saxena et al. (2012)55 pointed out that PSA is not only a
biomarker of prostate cancer and a known downstream target
of the androgen receptor, but it is also required for AR mRNA
and protein expression. Similarly, several authors reported that
AR inhibition resulted in a marked decrease in cell prolifer-
ation.57,58 Thus, the observed eﬀect of urolithins on prostate
cancer cells could be due to their possible interference in this
cross-talk and the reduction of PSA and AR levels.
A possible manner by which urolithins could interfere with
the previously mentioned AR-PSA cross-talk is by displaying
phytoestrogen-like activity. In this direction, the modulation of
hormone receptors by phenolic dietary components, such as
isoflavones, has been widely studied. Some authors compared
urolithins with several phytoestrogens, such as genistein, daid-
zein, resveratrol and enterolactone. These authors reported an
interference caused by urolithins in endocrine pathways pro-
posing them as possible phytoestrogens.29 In this sense, the
estrogenic and anti-estrogenic activity reported for urolithins
has been related to their interaction with the estrogen receptor
in human breast cancer cells (MCF-7).29 However, phytoestro-
gens, such as genistein, do not only interact with the estrogen
receptor but have also been shown to decrease AR levels in
LNCaP cells, and to cause a reduction in the binding of
nuclear proteins to an ARE.59 Considering all of the above, we
explored if urolithins were able to exert an eﬀect over the
androgen receptor, similar to that induced by phytoestrogens.
In our study we demonstrate that the activation of the PSA pro-
moter by DHT was blocked upon incubation with urolithins.
The reduced activation of PSA, which is an AR-regulated pro-
moter, could be explained by the decrease in the binding of
nuclear proteins to a consensus ARE, which under our con-
ditions was an 86% reduction. In addition, the binding of AR
to AREs was reduced by 32% after direct incubation of
untreated nuclear proteins with UA (data not shown). Hence,
the decrease in transcription caused by urolithins over PSA
levels was due to a direct eﬀect on the PSA promoter. Our
results are in keeping with those observed by Larrosa
(2006)28,29 and colleagues who studied the binding aﬃnity of
urolithins to the estrogen receptor in breast adenocarcinoma
cells. These authors observed a higher binding aﬃnity for uro-
lithin A than for urolithin B, similar to our results in which a
higher decrease in binding was observed upon incubation
with UA when compared to UB.
It is important to note that PSA is fundamental in the
pathophysiology of prostate cancer. It stimulates oxidative
stress in LNCaP and PC3 cells,60 and is also involved in tumor
invasion and metastasis.61 Considering its role in prostate
cancer progression, we explored if the pronounced decrease of
PSA levels upon urolithin incubation would result in an
increase in apoptosis. Urolithins indeed caused an increase in
apoptotic activity in LNCaP cells. Moreover, the increase in
apoptosis upon incubation with urolithins was correlated with
a decrease in the expression of Bcl-2, a critical regulator of the
apoptotic pathway, and a potent suppressor of apoptosis.62
Human tumors usually express high levels of Bcl-2 protein and
in prostate cancer its levels correlate with high levels of PSA.36
Thus, the decrease in Bcl-2 and the apoptotic activity induced
upon incubation with urolithins could be linked to the inhi-
bition of PSA by these compounds. Other authors have
reported that juglone, a non-polyphenolic compound found in
roots and leaves of the walnut tree, can cause apoptosis in
prostate cancer cells, in this case, associated with mitochon-
drial dysfunction and activation of caspases 3 and 9.63
5. Conclusion
Our results provide new insights into the eﬀect metabolites of
a common dietary component have on molecular mechanisms
involved in prostate carcinogenesis, which could in turn
provide a foundation for developing strategies for disease pre-
vention. The eﬀect of dietary agents on cancer can be used to
identify molecular therapeutic targets, and used as part of a
chemo-preventive strategy. Dietary intervention targeting mul-
tiple pathways might, therefore, be an eﬀective therapeutic
approach, either alone, or in conjunction with targeted
pharmaceutical agents.
In summary, we demonstrated a reduction in PSA and AR
levels induced by urolithins. This eﬀect could be due to a
decreased binding of the AR to AREs, and to decreased levels
of the androgen receptor resulting in PSA transcription inhi-
bition. An induction of apoptosis in LNCaP cells was also
observed, which may be caused by the down-regulation of AR
and PSA, as well as a decrease of Bcl-2 protein levels. A diet
high in ET-rich foods, such as walnuts, provides a considerable
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intake of pedunculagin and its metabolites, urolithins, which
could assist in the prevention of prostate cancer in men.
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ABSTRACT 
Introduction: Walnuts contain several bioactive compounds, including pedunculagin, a 
polyphenol metabolized by microbiota to form urolithins such as urolithin A. Urolithin A has 
several known biological effects on cancer cell models, but its effect on whole genome 
expression in prostate cancer cells is unknown. The aim of this study was to determine gene 
expression changes in prostate cancer cells upon incubation with urolithin A. 
Material and Methods: We performed a genomic analysis to study the effect of urolithin A on 
LNCaP prostate cells. Cells were incubated with 40 µM UA for 24 hours. Then, total RNA was 
extracted and hybridized to Affymetrix Human Genome U219 Array. Microarray results were 
analyzed using the GeneSpring v13 software. Differentially expressed genes (p < 0.05, Fold 
67
Change > 2) were used to perform Biological Association Networks. The activation of p21 
promoter was assessed by luciferase activity. Cell cycle was analyzed by flow cytometry and 
apoptosis was measured both by the rhodamine method and by caspase 3/7 activation. Cell 
viability was determined by the MTT assay. 
Results: We identified two gene nodes, FN-1 and CDKN1A, among the differentially expressed 
genes upon UA treatment. The overexpression of CDKN1A was validated at the mRNA and 
protein levels and p21 promoter activation was also observed.  Cell cycle analyses showed an 
increase in G1-phase cell population upon incubation with UA, which also resulted in apoptosis 
and caspase 3/7 activation.  
Conclusion:  Our results indicate a clear effect of urolithin A on whole genome expression in a 
prostate cancer cell model. The significant up regulation of p21, which has a known role in cell 
cycle and apoptosis, correlated with an increased percentage of cells in the G1 phase of the cell 
cycle and in apoptosis. These results further validate the multi-targeted effects of urolithins and 
the potential role of urolithin A as a chemo-preventive agent for prostate cancer. 
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an increase in G1-phase, and we also observed an induc-
tion of apoptosis and caspases 3 and 7 activation upon UA 
treatment.
Conclusion Our results indicate a potential role of UA as 
a chemopreventive agent for prostate cancer.
Keywords Urolithin A · Walnuts · Ellagitannins cancer 
prevention
Introduction
Compounds with anticancer activity that are naturally 
found in the diet can represent a particularly efficient thera-
peutic adjuvant. One such type of bioactive compounds is 
polyphenols, which exert their anticancer effects by several 
mechanisms, such as decreasing the pro-oxidative effect of 
carcinogenic agents [1, 2], modulation of cancer cell sign-
aling [3, 4], altering cell cycle progression [5], promot-
ing apoptosis [6, 7] and modulating enzymatic activities 
[8]. Polyphenols have also been shown to act on multiple 
targets involved in inflammation (tumor necrosis factor, 
TNF) [9], angiogenesis (vascular endothelial growth factor, 
VEGF) [10], and drug and radiation resistance (multi-drug 
resistance protein, MDR) [11].
Walnuts are a common dietary component in many 
places around the world. It is well documented that the 
most abundant polyphenols in walnuts are ellagitannins 
(ETs), mainly pedunculagin [12, 13]. ETs exhibit structural 
diversity according to food source [12]. Previous studies 
of rat intestinal contents showed that ETs could be hydro-
lyzed to ellagic acid (EA) at the pH found in the small 
intestine and cecum [14, 15]. EA is further metabolized 
by gut flora to urolithins, mainly urolithin A (UA) and B 
(UB) [16] and is probably formed in the colon [15]. These 
Abstract 
Purpose Walnuts contain several bioactive compounds, 
including pedunculagin, a polyphenol metabolized by 
microbiota to form urolithins, namely urolithin A (UA). 
The aim of this study was to determine gene expression 
changes in prostate cancer cells after incubation with UA.
Methods We performed a genomic analysis to study the 
effect of UA on LNCaP prostate cells. Cells were incu-
bated with 40 µM UA for 24 h, and RNA was extracted 
and hybridized to Affymetrix Human Genome U219 array. 
Microarray results were analyzed using GeneSpring v13 
software. Differentially expressed genes (p < 0.05, fold 
change > 2) were used to perform biological association 
networks. Cell cycle was analyzed by flow cytometry and 
apoptosis measured by the rhodamine method and by cas-
pases 3 and 7 activation. Cell viability was determined by 
MTT assay.
Results We identified two nodes, FN-1 and CDKN1A, 
among the differentially expressed genes upon UA treat-
ment. CDKN1A was validated, its mRNA and protein lev-
els were significantly up-regulated, and the promoter acti-
vation measured by luciferase. Cell cycle analysis showed 
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urolithins circulate in blood and can reach many of the tar-
get organs where the effects of ellagitannins are observed 
[17]. The occurrence of ETs and EA in the bloodstream is 
almost negligible, but their derived metabolites, urolithins, 
can reach micromolar concentrations in plasma [18]. It is 
important to note that urolithin levels in plasma and urine 
after ingestion of ETs-rich foods can differ between indi-
viduals due to their gut microbiota [15].
Like other polyphenols, ETs, EA and their derived 
metabolites possess varied biological activities which 
suggest that they could have beneficial effects on human 
health [18]. The role of ETs in several molecular pathways 
related to cancer initiation, development and progression 
has been assessed in in vitro [19, 20] and in vivo studies 
[21]. Our group has previously assessed the effect that UA 
and UB exert on LNCaP prostate adenocarcinoma cells. 
We observed a clear down-regulation especially by UA 
of androgen receptor (AR) and prostate-specific antigen 
(PSA) expression, both important targets in prostate cancer 
progression [22].
Even though there is emerging evidence that walnut 
polyphenols can reduce the risk of developing certain can-
cers, the molecular mechanisms underlying their chemo-
preventive effect still remain poorly known. Nutrigenomics 
is an approach that favors the understanding of how dietary 
components influence molecular pathways, and how this 
influence can modulate signaling in early phases of dis-
ease, such as in cancer. Nutrients and food bioactive com-
pounds are considered to be “signaling molecules” that, 
through cellular sensing mechanisms, can produce changes 
in gene expression at the transcriptomic, proteomic, and 
metabolomic levels [23]. Therefore, considering our pre-
vious results, we were encouraged to further explore 
the effect of UA upon LNCaP gene expression through a 
genomic approach. The aim of our study was to determine 
the effect of urolithin A, the main human metabolite of 
walnut polyphenols, on gene expression in a prostate can-
cer cell line using microarrays. We also performed biologi-
cal association networks (BANS) to generate node genes 
that constituted important targets for further exploration. 
Furthermore, we evaluated the effect of UA on cell cycle, 
apoptosis and proliferation.
Materials and methods
Chemicals
Urolithin A (UA; 3,8-dihydroxy-6H-dibenzo[b,d]pyran-6-
one, 95 % purity) was synthesized by the Department of 
Organic Chemistry, School of Pharmacy at the University 
of Barcelona (Barcelona, Spain). Urolithin A was resus-
pended in DMSO.
Cell culture
LNCaP (androgen responsive) human prostate adenocarci-
noma cell line was routinely grown in Ham’s F-12 medium, 
supplemented with 7 % (V/V) fetal bovine serum (FBS, both 
from GIBCO, Invitrogen, Barcelona, Spain), sodium penicil-
lin G and streptomycin, and was maintained at 37 °C in a 
humidified atmosphere containing 5 % CO2. Different num-
ber of cells, depending on the assay, were incubated with 
40 µM urolithin A since we have previously used at this con-
centration [22] which can be found in plasma after consump-
tion of pedunculagin-rich foods [18]. The final concentration 
of DMSO in the culture medium was always ≤0.2 %.
Microarrays
Gene expression was analyzed by hybridization to Affym-
etrix Human Genome U219 array plate, which measures 
gene expression of more than 36,000 transcripts and vari-
ants that represent more than 20,000 genes. LNCaP cells 
(350,000) were incubated with 40 μM urolithin A for 24 h. 
Total RNA was prepared from triplicate samples using 
RNAeasy minikit (Qiagen) following the recommenda-
tions of the manufacturer. RNA quality was tested by Agi-
lent Technologies using 2100 Bioanalyzer Eukaryote Total 
RNA Nano Series II. Labeling, hybridization and detec-
tion were carried out following the manufacturer’s speci-
fications at the IDIBAPS Genomic Service from Hospital 
Clínic, Barcelona. In brief, cRNA was labeled with biotin, 
purified, fragmented and hybridized onto the platform, 
using the GeneChip HT 3′IVT Express Kit. Afterward, 
the GeneTitan® Multi-Channel Instrument (Affymetrix) 
was used to hybridize, wash and stain. Microarrays were 
scanned using the Genechip Scanner 3000.
Microarray data analyses
Genomic analyses were carried out using the GeneSpring 
GX software v.13 (Agilent Technologies). Data were pro-
cessed by RMA (robust multi-array average) normalization 
in log2 base scale and using a baseline transformation to 
the median of control samples. Differentially expressed 
genes were obtained by applying a p value cutoff of less 
than 0.05, and a fold change of expression of at least two-
fold as described in Selga et al. [24]. Normalized and raw 
data were submitted to the Gene Expression Omnibus data-
base (GEO). The GEO series GSE65527 was assigned for 
the data set.
Generation of biological association networks (BANs)
BANs were constructed with the aid of the pathway anal-
ysis within the GeneSpring v.13 (Agilent) as described 
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by Selga et al. [25] starting with the list of differentially 
expressed genes after 24 h of incubation with UA. NLP net-
work discovery was performed using an advanced analysis 
with an expand interactions algorithm to assess relations 
among entities. The software builds an association network 
using our data and bibliographic interaction databases. Rel-
evant network associations were curated.
Real‑time RT‑PCR
Total RNA was extracted from LNCaP using RNAeasy 
minikit (Qiagen) in accordance with the manufacturer’s 
instructions. Complementary DNA (cDNA) was synthe-
sized as described by Oleaga et al. [26]. RNA concentra-
tion and purity was checked using a Nanodrop spectro-
photometer system (ND-1000 3.3 Nanodrop Technologies, 
Wilmington, DE, USA). mRNA levels were determined by 
StepOnePlus™ Real-Time PCR Systems (Applied Biosys-
tems, Barcelona, Spain) using 3 μL of cDNA and specific 
Taqman probes (Applied Biosystems, Barcelona, Spain) for 
CDKN1A (Hs00355782) and FN-1 (Hs00365052) genes 
and APRT (Hs00975725) as an endogenous control.
Western blot
LNCaP cells (350,000) were plated on 35 mm/well 6-well 
dishes and treated the day after with UA. After 24 h of incu-
bation, cells were collected and centrifuged for 5 min at 
800×g at 4 °C. The cell pellets were suspended in 200 µL 
of Lyss buffer (0.5 M NaCl, 1.5 mM MgCl2, 1 mM EGTA, 
10 % glycerol 1 % Triton x_100, 50 mM HEPES, pH 7.9 
all from Applichem, Barcelona, Spain), and 10 µL protease 
inhibitor cocktail (from Sigma-Aldrich, Madrid, Spain). 
The cell lysate was kept on ice for 60 min vortexing every 
15 min. Cellular debris was removed by centrifugation at 
15,000×g at 4 °C for 10 min. A 5 μL aliquot of the extract 
was used to determine the protein concentration using the 
Bradford assay (Bio-Rad, Barcelona, Spain).
Whole-cell extracts (100 µg) were resolved in 12 % 
SDS–polyacrylamide gels and transferred to PVDF mem-
branes (Immobilon P, Millipore, Madrid, Spain) using a 
semidry electroblotter. Membranes were probed overnight 
at 4 °C with primary antibody against p21 (1:200 dilution; 
sc-397 from Santa-Cruz Biotechnology Inc., Heidelberg, 
Germany). Signal was detected by secondary horseradish 
peroxidase-conjugated anti-rabbit (1:2500; Dako, Den-
mark) antibody and enhanced chemiluminescence using 
the ECL™ Prime Western Blotting Detection Reagent, as 
recommended by the manufacturer (GE Healthcare, Barce-
lona, Spain). Chemiluminescence was detected with Image-
Quant LAS 4000 Mini technology (GE Healthcare, Barce-
lona, Spain). Normalization of the blots was performed by 
incubation with an antibody against tubulin (1:800 dilution, 
sc-5286 from Santa-Cruz Biotechnology Inc., Heidelberg, 
Germany).
Transfection and luciferase assay
LNCaP cells (350,000) were plated in 35 mm/well 6-well 
dishes the day before transfection. Medium (2 mL) was 
renewed before transfection, which was performed using 
FuGENE 6 (Roche, Barcelona, Spain). For each well, 
transfection reagent was incubated for 5 min in 100 µL of 
antibiotic and serum-free medium, followed by the addi-
tion of plasmid DNA and incubated for another 20 min at 
a ratio of 3:1 (µL of transfection reagent: µg of plasmid 
DNA). One microgram of plasmid DNA, either the basic 
vector or WWP-Luc promoter, a p21 promoter construction 
in front of a luciferase reporter gene, was used for trans-
fection. WWP-Luc (p21/WAF1 promoter) was obtained 
from Dr. Bert Vogelstein from the Johns Hopkins School 
of Medicine.
Incubation with 40 µM of UA was performed 6 h after 
transfection, and luciferase activity was determined 24 h 
after transfection. Cell extracts were prepared by lysing 
cells with 100 µL of Reporter Lysis Buffer (2 mM DTT, 
2 mM EDTA, 10 % glycerol, 1 % Triton X_100, 25 mM 
Tris–phosphate, pH 7.8). The lysate was centrifuged at 
12,000×g for 2 min at 4 °C to pellet cell debris, and super-
natants were transferred to a fresh tube. Fifteen microliters 
of the extract was added to 15 µL of the luciferase assay 
substrate (Promega, Madrid, Spain) at room temperature. 
Luminescence was measured using the Glomax™ 20/20 
Luminometer (Promega, Madrid, Spain) and expressed 
as relative luminescence units (RLU). Luciferase results 
were normalized by total protein concentration in the cell 
lysates. Protein concentration was determined by the Brad-
ford assay (Bio-Rad, Barcelona, Spain) according to the 
manufacturer’s protocol.
Cell cycle analysis
After treating cells with for 24 h, cells were recovered by 
centrifugation (800×g, 3 min) and washed once with cold 
PBS. The pellet was resuspended in 500 µL cold PBS 
and 4500 μL cold 70 % ethanol and left at −20 °C over-
night. The cells were then centrifuged, and the pellet was 
washed once with cold PBS, resuspended in PBS, RNAse 
A (2 mg/mL, final concentration), 0.1 % Triton X_100 and 
stained with propidium iodide (5 mg/mL final concentra-
tion) for 1 h and analyzed by flow cytometry. Flow cyto-
metric experiments were carried out using an Epics XL 
flow cytometer (Coulter Corporation, Hialeah, Florida). 
Excitation of the sample was done using a standard 488-nm 
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air-cooled argon-ion laser at 15 mW power. Forward scat-
ter (FSC), side scatter (SSC) and red (620 nm) fluorescence 
for PI were acquired. Aggregates were excluded gating 
single cells by their area versus peak fluorescence signal. 
DNA analysis on single fluorescence histograms was done 
using Multicycle software (Phoenix Flow Systems, San 
Diego, CA).
Apoptosis
Apoptosis was determined by two methods: Rhodamine 
method and Caspase-Glo 3/7 assay (Promega, Madrid, 
Spain) which measures caspase activation. For the rho-
damine method, LNCaP cells (250,000) were plated in 
35 mm/well 6-well dishes with 2 mL complete F-12 
medium and 24 h after, they were treated with increas-
ing concentrations of UA. Staurosporine (1 µM) (Sigma-
Aldrich, Madrid, Spain) was used as a positive control. 
Rhodamine (final concentration 5 ng/mL) (Sigma-Aldrich, 
Madrid, Spain) was added for 30 min, and the cells were 
collected, centrifuged at 800×g at 4 °C for 5 min, and 
washed once in PBS. The pellet was suspended in 500 mL 
PBS plus propidium iodide (PI) (final concentration 5 mg/
mL) (Sigma-Aldrich, Madrid, Spain). Flow cytometry data 
were analyzed using the Summit v4.3 software. The per-
centage of Rho-negative and PI negative cells corresponds 
to the apoptotic population.
For the Caspase-Glo 3/7 assay, 10,000 cells per well 
were plated in a 96-well plate in 100 µL F12-complete 
medium. After 24 h, cells were incubated with UA for 24 h. 
The following day, 100 µL of Caspase-Glo 3/7 reagent was 
added. After 1 h of incubation, luminescence was measured 
using a Modulus™ Microplate luminometer (Turner Bio-
systems, Promega, Madrid, Spain). F12-complete medium 
and the reagent were considered the blank control and 
untreated cells as background.
Cell viability
Cell viability was measured by MTT assay. Cells were 
plated in 35 mm/well 6-well dishes in F12 medium, and 
cells were incubated with increasing concentrations of UA 
for 24 h. After incubation, 0.63 mM of 3-(4,5-dimethylth-
iazol-2-yl)-2,5-diphenyltetrazolium bromide and 18.4 mM 
of sodium succinate (both from Sigma-Aldrich, Madrid, 
Spain) were added to the culture medium and incubated 
for 3 h at 37 °C. Then, the medium was removed and the 
solubilization reagent (0.57 % acetic acid and 10 % sodium 
dodecyl sulfate in dimethyl sulfoxide) (Sigma-Aldrich, 
Madrid, Spain) was added. Cell viability was measured at 
570 nm in a WPA S2100 Diode Array spectrophotometer 
(Biochrom Ltd., Cambridge, UK).
Statistical analyses
For the RT-PCR determinations, western blot analyses and 
apoptosis assays, values are expressed as the mean ± SE of 
three independent experiments. Data were analyzed using 
one-way ANOVA followed by Tukey’s post hoc multiple 
range test by using the SPSS software v.21. The difference 
between groups was considered statistically significant at 
p < 0.05.
Results
Effect of urolithin A incubation in LNCaP gene 
expression
Gene expression profile was compared between LNCaP 
cells incubated with 40 µM UA for 24 h versus control 
(vehicle-treated cells). GeneSpring GX software v.13 
was used to analyze the results and a list of twofold dif-
ferentially expressed genes and a p value cutoff of <0.05 
was created. UA incubation caused the up-regulation of 
37 genes and down-regulation of 74 genes. Differentially 
expressed genes are presented in Table 1A, B. The data 
reported in this paper are accessible through GEO series 
accession number [GSE65527].
Generation of biological association networks
A biological association network (BAN) was constructed 
using pathway architect within GeneSpring v.13 using the 
list of differentially expressed genes (Table 1A, B) upon 
incubation with UA. In the generated network, CDKN1A 
that encodes for p21 appeared as a prominent node and 
was chosen for further validation due to its relation to can-
cer progression (Fig. 1), another gene to note in the BAN 
was fibronectin-1 (FN-1). Changes in gene expression of 
both nodes are shown in Table 1A, B. CDKN1A was up-
regulated by 260 %, while FN-1 was down-regulated by 
48 %.
Validation of p21 changes at the mRNA and protein 
levels
For the validation of CDKN1A, LNCaP cells were incu-
bated with 40 μM UA for 24 h. Total RNA was extracted, 
and p21 expression was analyzed by real-time RT-PCR. A 
2.6-fold increase in CDKN1A mRNA levels was observed 
after 24-h incubation with UA (Fig. 2a). P21 protein levels 
were also determined upon incubation of LNCaP cells with 
UA, and an 8.6-fold increase was observed in these condi-
tions (Fig. 2b).
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Table 1  (A) List of overexpressed genes, (B) list of underexpressed genes
Gene symbol Gene title p value (corrected) FC Raw value
(A)
ANTXR1 Anthrax toxin receptor 1 0.018071683 3.9283698 33–131
HMGCS2 3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial) 0.041272584 3.2182467 311–1001
SLC1A1 Solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, 
system Xag), member 1
0.04198332 2.9483755 69–203
RBKS Ribokinase 0.04065924 2.890072 82–238
SFRS11 Serine/arginine-rich splicing factor 11 0.049647037 2.8698597 285–819
FTH1 Ferritin, heavy polypeptide 1 0.029451594 2.8085105 890–2502
RPL31 Ribosomal protein L31 0.048858333 2.7897265 264–736
RNFT2 Ring finger protein, transmembrane 2 0.04847244 2.6944962 102–276
ABCG1 ATP-binding cassette, sub-family G (WHITE), member 1 0.041132696 2.6784973 79–212
SNORD72 Small nucleolar RNA, C/D box 72 0.041381806 2.6759524 377–1010
CDKN1A Cyclin-dependent kinase inhibitor 1A (p21, Cip1) 0.03852722 2.605698 1449–3776
TCTEX1D2 Tctex1 domain containing 2 0.033454563 2.5897472 152–395
C6orf52 Chromosome 6 open reading frame 52 0.041132696 2.5859122 180.93625
SDC4 Syndecan 4 0.018071683 2.5526035 253–645
NUTF2 Nuclear transport factor 2 0.03852722 2.5449026 59–152
PIK3R3 Phosphoinositide-3-kinase, regulatory subunit 3 (gamma) 0.039309744 2.4860854 667–1658
HSPA5 Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) 0.048546728 2.4627695 145–358
DNAJC21 DnaJ (Hsp40) homolog, subfamily C, member 21 0.04065924 2.3872724 27–65
ARMCX3 Armadillo repeat containing, X-linked 3 0.048788916 2.3852787 159–380
C17orf108 LYR motif containing 9 0.048965555 2.3784144 111–266
SAP18 Sin3A-associated protein, 18 kDa 0.044830944 2.3029501 59–137
C9orf103  idnK, gluconokinase homolog (E. coli) 0.021912582 2.2767186 108–247
SERPINB5 Serpin peptidase inhibitor, clade B (ovalbumin), member 5 0.039116967 2.1881664 87–192
KRCC1 Lysine-rich coiled-coil 1 0.04073255 2.178822 95–209
DDB2 Damage-specific DNA binding protein 2, 48 kDa 0.039309744 2.1729174 229–481
PLRG1 Pleiotropic regulator 1 0.046348132 2.158798 151–326
GNG7 Guanine nucleotide binding protein (G protein), gamma 7 0.048489492 2.1230555 92–196
RNF32 Ring finger protein 32 0.03852722 2.1158345 43–92
DDB2 Damage-specific DNA binding protein 2, 48 kDa 0.029451594 2.096718 222–482
SIPA1L1 Signal-induced proliferation-associated 1 like 1 0.046348132 2.0962265 40–84
KANK1 KN motif and ankyrin repeat domains 1 0.046864968 2.0880623 35–75
GSTA4 Glutathione S-transferase alpha 4 0.044622324 2.0603788 324–669
BBC3 BCL2 binding component 3 0.048489492 2.059085 128–264
UGT2B15 UDP glucuronosyltransferase 2 family, polypeptide B15 0.03852722 2.0504327 4175–8561
SESN1 Sestrin 1 0.039309744 2.0473588 674–1381
PGRMC2 Progesterone receptor membrane component 2 0.048489492 2.0238128 645–1305
C11orf95 Chromosome 11 open reading frame 95 0.04801972 2.013529 43–88
(B)
TARP TCR gamma alternate reading frame protein 0.0411327 −20.279497 832–41
LAMA1 Laminin, alpha 1 0.03482863 −10.690396 336–31
TRPM8 Transient receptor potential cation channel subfamily M member 8 0.04127258 −9.334312 344–36
SEMA6D Sema domain, transmembrane domain (TM), and cytoplasmic domain, (sema-
phorin) 6D 
0.04854673 −6.9679465 287–41
TM4SF1 Transmembrane 4 L six family member 0.04653614 −6.4500413 288–44
NKX3-1 NK3 homeobox 1 0.03345456 −6.02152 5460–1414
KLK2 Kallikrein 2 0.03345456 −5.918217 2539–447
ARHGAP28 Rho GTPase activating protein 28 0.03930974 −5.5213523 483–196
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Table 1  continued
Gene symbol Gene title p value (corrected) FC Raw value
TMPRSS2 Transmembrane protease, serine 2 0.04127258 −4.916592 50–102
MAF v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog 0.03852722 −4.5020537 168–37
FKBP5 FK506 binding protein 5 0.04127258 −4.393235 345–78
STK39 Serine threonine kinase 39 0.04653614 −4.3851995 2229–807
HPGD Hydroxyprostaglandin dehydrogenase 15-(NAD) 0.03852722 −4.188455 48–11
TMEM100 Transmembrane protein 100 0.03345456 −4.053033 57–14
PLA1A Phospholipase A1 member A 0.03852722 −4.0299063 112–27
MCCC2 Methylcrotonoyl-CoA carboxylase 2 (beta) 0.04896556 −4.0113063 1789–446
CENPN Centromere protein N 0.0481307 −3.989921 4778–1918
PMEPA1 Prostate transmembrane protein, androgen induced 1 0.04198332 −3.935241 1204–306
EAF2 ELL associated factor 2 0.04848949 −3.7372491 442–118
TUBA3D Tubulin, alpha 3d 0.04878892 −3.7160873 159–42
ABCC4 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 0.04713093 −3.51927 79–22
IGF1R Insulin-like growth factor 1 receptor 0.0411327 −3.3870313 254–84
SLC38A4 Solute carrier family 38, member 4 0.04848949 −3.297615 38–11
INPP4B Inositol polyphosphate-4-phosphatase, type II 0.03852722 −3.2538679 80–24
FAM65B Family with sequence similarity 65, member B 0.02945159 −3.0884745 657–228
HOMER2 Homer homolog 2 (drosophila) 0.04554693 −3.0316038 178–59
TNFAIP8 Tumor necrosis factor, alpha-induced protein 8 0.04854673 −2.9435992 64–22
CAB39L Calcium binding protein 39-like 0.03852722 −2.9318016 814–279
ELL2 Elongation factor, RNA polymerase II, 2 0.04651458 −2.9182982 275–94
SLC16A6 SLC16A6 pseudogene 1 0.04964704 −2.8450818 436–153
NTNG1 Netrin G1 0.04653614 −2.84009 130–45
STK39 Serine threonine kinase 39 0.04848949 −2.762043 2229–807
NDRG1 N-myc downstream regulated 1 0.04847244 −2.6652703 1049–393
SLC4A4 Solute carrier family 4 (sodium bicarbonate cotransporter), member 4 0.04462232 −2.5919237 634–244
ELOVL7 ELOVL fatty acid elongase 7 0.04964704 −2.5912743 113–43
MBOAT2 Membrane bound O-acyltransferase domain containing 2 0.04127258 −2.5849755 2675–1034
RAB3B RAB3B, member RAS oncogene family 0.04847244 −2.5677748 180–70
TMPO Thymopoietin 0.04462232 −2.519366 238–94
PDLIM5 PDZ and LIM domain 5 0.04854673 −2.502937 429–171
TBRG1 Transforming growth factor beta regulator 1 0.02191258 −2.5027993 614–245
LAMC1 Laminin, gamma 1 0.04127258 −2.4839528 1687–679
NEDD4L Neural precursor cell expressed, developmentally down-regulated 4-like, E3 
ubiquitin protein ligase 
0.04686497 −2.4582028 1155–495
KCND2 Potassium voltage-gated channel, Shal-related subfamily, member 2 0.04854673 −2.4482534 80–32
LANCL1 LanC lantibiotic synthetase component C-like 1 (bacterial) 0.04848949 −2.4360988 180–74
LCP1 Lymphocyte cytosolic protein 1 (L-plastin) 0.04848949 −2.3906643 1808–756
KCNMA1 Potassium large conductance calcium-activated channel, subfamily M, alpha 
member 1
0.02945159 −2.3443553 430–183
TFPI Tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) 0.04848949 −2.3411489 1841–786
IGSF5 Immunoglobulin superfamily, member 5 0.0411327 −2.2933848 55–25
TBRG1 Transforming growth factor beta regulator 1 0.04550014 −2.2920535 1645–717
AGL Amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase 0.04089165 −2.274828 167–73
SYT4 Synaptotagmin IV 0.04848949 −2.237817 2523–1226
SOAT1 Sterol O-acyltransferase 1 0.04360254 −2.228152 689–313
GCNT1 Glucosaminyl (N-acetyl) transferase 1, core 2 0.03852722 −2.2103882 82–37
HES1 Hes family bHLH transcription factor 0.03852722 −2.1978023 121–55
FKBP1A FK506 binding protein 1A 0.04848949 −2.1769133 353–162
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Effect of urolithin A on p21 promoter activity
To assess whether UA modulates the transcriptional acti-
vation of p21, we performed transient transfections in 
LNCaP cells using a luciferase reporter vector carrying the 
p21 promoter construct (WWP-luc) in the absence and in 
the presence of UA. UA-incubated cells (40 µM) showed 
a 3.5-fold increase on luciferase activity when compared 
to the vehicle-treated cells (Fig. 2c). As a control, cells 
transfected with the empty vector and un-transfected cells 
showed basal luminescence (Fig. 2c).
Urolithin A causes changes in the cell cycle
LNCaP cells were incubated with 40 µM UA to evaluate its 
effect over cell cycle. The results show a statistically signif-
icant increase in cells in the G1-phase after 24 h of incuba-
tion (Fig. 3a). Consequently, the increase in the percentage 
of G1 cells was accompanied by a decrease in cell number 
in both the S and G2/M phases.
Urolithin A causes apoptosis and caspases 3 and 7 
activation
We assessed the effect of urolithins on apoptosis using the 
rhodamine method. After incubating LNCaP cells with UA 
at two concentrations (10 and 40 μM) for 24 h, the percent-
age of apoptotic cells increased compared with the con-
trol (Fig. 4a). A dose-dependent increase in apoptotic cell 
population was observed, although a statistically significant 
increase (14 %) was seen only after incubation with 40 μM 
UA (Fig. 4b). In addition, we also measured caspases 3 and 
7 activation. Using the Caspase-Glo 3/7 assay, no apparent 
change was determined after incubation with 10 μM, but in 
accordance with the results using the rhodamine method, 
caspases 3 and 7 activation was significantly higher after 
incubation with 40 μM UA (Fig. 4c).
Effect of urolithin A on cell viability
Since UA caused changes in cell cycle distribution and 
induced apoptosis, we also measured cell viability after 
incubation with increasing concentrations of UA. UA 
caused a dose-dependent decrease in LNCaP cell viabil-
ity. This effect became particularly evident after incubation 
with 60 μM UA (Fig. 5).
Discussion
The main objective of this study was to investigate, through 
functional genomics, the effect of UA, a known metabolite 
Table 1  continued
Gene symbol Gene title p value (corrected) FC Raw value
TJP1 Tight junction protein 1 0.02945159 −2.11793 341–161
LIN7B Lin-7 homolog B (C. elegans) 0.04847244 −2.1050866 174–83
ADAMTS1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 0.0379042 −2.0998979 2939–1399
GNB4 Guanine nucleotide binding protein (G protein), beta polypeptide 4 0.0411327 −2.096679 1230–587
DHFR Dihydrofolate reductase 0.04964704 −2.090263 779–373
FN1 Fibronectin 1 0.02945159 −2.0699394 1475–711
FGFR1OP FGFR1 oncogene partner 0.04211903 −2.069577 787–380
PPAP2A Phosphatidic acid phosphatase type 2A 0.04848949 −2.0578847 4149–2016
C3orf58 Chromosome 3 open reading frame 58 0.0450805 −2.0526423 162–79
LIMCH1 LIM and calponin homology domains 1 0.04686497 −2.0517795 1748–852
LOC81691 Exonuclease NEF-sp 0.03852722 −2.0482614 189–92
PPFIA2 Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF) 0.04964704 −2.0405033 284–139
TMEM79 Transmembrane protein 79 0.02945159 −2.0395525 289–141
SCARB2 Scavenger receptor class B, member 2 0.04854673 −2.0371418 1189–583
MPHOSPH9 M-phase phosphoprotein 9 0.041381806 −2.024088 496–245
FAM3B Family with sequence similarity 3, member B 0.018071683 −2.0137253 38–18
ACTR3 ARP3 actin-related protein 3 homolog (yeast) 0.048858333 −2.01066 1516–754
KIF22 Kinesin family member 22 0.046348132 −2.0081372 576–287
ZNF385B Zinc finger protein 385B 0.044830944 −2.0049856 708–353
The table shows the list of differently expressed genes by 2.0-fold with a p value <0.05 obtained after cells treated with 40 µM UA and includes 
the gene symbol for all genes, and their associated title. The additional columns correspond to the corrected p value, the fold change in expres-
sion relative to the control group, and the changes in raw values
75
 Eur J Nutr
1 3
of ETs, on gene expression in LNCaP prostate adenocar-
cinoma cells. To do so, microarray analyses were per-
formed obtaining lists of differentially expressed genes. 
Then, a biological association network (BANs) analysis 
was performed to establish the relationship among the dif-
ferentially expressed genes and whether these interactions 
resulted in important nodes. Two main nodes were found, 
namely CDKN1A (encoding for p21 protein), which was 
overexpressed, and FN-1 (encoding for the extracellular 
glycoprotein, fibronectin), which was underexpressed. Due 
to the well-known anti-proliferative role of p21 in tumor 
cells, we decided to focus on exploring the effects that UA 
has on the transcriptional regulation of p21 and its role on 
the cell cycle and apoptosis.
The role of ETs in prostate cancer progression has been 
reported by several authors including ourselves [22, 27–30]. 
Using a pomegranate fruit extract, Malik et al. [30] deter-
mined the increase in Bax and p21, and the decrease in 
Bcl-2 in PC3 androgen-independent cells. In a xenograft 
model, the pomegranate extract was able to reduce PSA 
secretion and tumor growth. Albrecht et al. [28] used four 
different pomegranate extracts (fruit, pericarp and 2 oils) to 
assess cell cycle progression and apoptosis in LNCaP, PC-3 
and DU 145. These authors observed a twofold increase in 
p21 in prostate cancer cells with fermented juice polyphe-
nols. Punicalagin, ellagic acid (EA) and total pomegranate 
tannin (TPT) were able to decrease the viability of human 
oral, prostate and colon tumor cells; however, superior 
activity was obtained with pure pomegranate juice (PJ). 
Similarly, PJ, punicalagin, EA and TPT induced apoptosis 
in HT-29 cells Seeram et al. [19]. González-Sarrias et al. 
[27] analyzed prostate tissue from volunteers after intake of 
ET-rich foods. The authors did not observe significant dif-
ferences between benign prostate hyperplasia and prostate 
cancer. They concluded that the results obtained in the dif-
ferent groups might be influenced by the high variability 
between individuals, by the heterogeneity of the prostate 
tissues obtained by different procedures and by the use of 
small specimens that may not be representative of neighbor-
ing tissues. It is important to note that other variables such 
Fig. 1  Biological association network. The list of differentially expressed genes after 24-h incubation with 40 µM urolithin A was used to con-
struct a BAN using the pathway analysis software within GeneSpring v13. The expanded BAN shows CDKN1A and FN-1 as node genes
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as disease stage and treatment could influence the effect of 
ETs over proliferation and other markers of PCa develop-
ment and progression, including CDKN1A. In addition, 
in vivo levels of ET metabolites are highly variable and 
dependent on host’s microbiota. In this direction, Seeram 
et al. [31] determined that ET metabolites were concen-
trated at high levels in mouse prostate, colon and intestinal 
tissues after administration of pomegranate extract and UA. 
Furthermore, they determined that pomegranate extract was 
able to inhibit the growth of a tumor xenograft performed 
with LAPC-4 prostate cancer cells by more of 50 %.
In the present study, we are able to associate the effects 
of the specific metabolite of ET, UA, with the changes in 
cell cycle distribution, proliferation and apoptosis in pros-
tate cancer cells. We began our approach using a genomic 
strategy that allowed us to identify p21 as a relevant gene 
node in the network of differentially expressed genes pro-
voked by UA action. The concentration of 40 µM UA was 
chosen because it is in the order of low micromolar levels, 
similar to what can be found in plasma after consump-
tion of ET-rich foods [16, 17, 32] and was not cytotoxic 
to LNCaP cells [22]. In addition, most of the biological 
Fig. 2  CDKN1A mRNA and protein levels. a CDKN1A mRNA 
levels determined by real-time RT-PCR. Bars represent CDKN1A 
mRNA levels in LNCaP cells either control (0.10 % of DMSO) or 
treated with 40 µM UA during 24 h. Results are expressed in fold 
changes compared to the untreated cells and normalized using APRT 
as an endogenous control. They are the mean ± SE of three different 
experiments. ***p < 0.001. b Determination of p21 protein levels by 
western blot. Bars represent p21 protein levels in LNCaP cells either 
control (0.10 % of DMSO) or treated with 40 µM UA. Results are 
expressed as fold change compared to the untreated cells and repre-
sent the mean ± SE of three different experiments. ***p < 0.001. c 
p21 promoter activity in LNCaP cells. Cells were transfected with a 
luciferase reporter vector carrying the p21 promoter, and 6 h later, 
they were incubated with 40 µM UA. Results are expressed as lucif-
erase relative units/total protein compared to control. They are the 
mean ± SE of three different experiments. ***p < 0.001
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experiments with urolithins using human cell lines are per-
formed in this range of concentrations [18, 31, 33]. In our 
approach with cultured cells, a single dose of the minimum 
concentration of UA in order to see a transcriptional effect 
was used. Given that the study was performed for a period 
of 24 h, one single dose was enough to observe changes in 
mRNA expression levels.
P21 is a cell cycle arrest inductor that functions as both 
a sensor and an effector of multiple anti-proliferative sig-
nals. It should be noted that under certain conditions, p21 
has also been shown to have an oncogenic role, though this 
effect depends on the cellular localization, apoptotic stim-
uli and type of cancer [34]. Specifically, in prostate can-
cer, forced expression of p21 by transfection of adenoviral 
a vector had inhibitory effects on cancer cell growth [35]. 
Taking into account the significant up-regulation of p21 by 
UA, both at mRNA and protein levels, we decided to further 
explore the potential effect of this metabolite on cell cycle 
progression, particularly since this interaction has not been 
previously assessed in an androgen-dependent prostate can-
cer cell model. P21 inhibits cell cycle progression primarily 
through the inhibition of cyclin-dependent kinases result-
ing in G1 cell cycle arrest and a block in the transition in S 
phase [36]. Accordingly, our results show that UA caused 
an alteration in the cell cycle with an accumulation of cells 
in G1 and a reduction in S and G2. The role of p21 in can-
cer is complex, and among its well-known activities, p21 
mediates p53-dependent G1 growth arrest, although recent 
evidence also indicates that p21 is an effector of multiple 
tumor suppressor pathways independent of p53 [36]. In 
CaSki cervical carcinoma cells, EA, the precursor of UA, 
induced an elevation of p21 mRNA and protein levels, but 
no relevant increase level in p53 mRNA and protein lev-
els were detected. These authors suggested the activation 
of p21 by EA could be either through a p53-independent 
mechanism or by a p53-dependent mechanism that does 
not involve changes in p53 protein levels [37]. Therefore, 
although p21 activation can depend on p53, it appears that 
the induction of p21 by ETs is not dependent upon p53 
levels.
We had previously assessed the effect that urolithins 
have on the modulation of the AR, which is fundamen-
tal in prostate cancer carcinogenesis and determined the 
inhibition in AR and PSA expression after incubating 
LNCaP cells with urolithins A and B. Down-regulation of 
PSA (KLK3) by UA was also detected in the microarray 
Fig. 3  Cell cycle distribution after incubation with urolithin A. 
a Bars represent the cell cycle phase distribution of control or UA-
treated cells. Results are expressed as the mean of three experi-
ments ± SE of relative cell population (%) **p < 0.005. Represent-
ative flow cytometry histograms of cell cycle of LNCaP cells upon 
incubation with either DMSO (b) or with UA 40 µM (c) for 24 h
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experiments. However, the decrease in fold change was 
-1.93 with a p value of less than 0.05; therefore, it was not 
included in Table 1A, B corresponding to fold changes 
higher than 2. In the case of AR, its down-regulation, as 
previously described [22], takes place between 9 and 12 h 
of treatment with UA, and it does not appear underex-
pressed in the microarray at 24 h.
Taking into account that a link between AR, PSA levels 
and p21 in a prostate cancer cell model had been explored 
through mechanistic studies [35], it was of interest to 
explore the role that urolithins might have in the possi-
ble interaction between AR, PSA and p21. Wang and col-
leagues [35] described that overexpression of the AR was 
responsible for p21 silencing and possibly for creating 
resistance to apoptosis in advanced prostate cancer. This 
inhibition of p21 by AR levels was androgen response ele-
ment (ARE) and androgen dependent, which might nega-
tively impact the sensitivity to apoptosis. In their study, a 
50 % reduction in AR levels was accompanied by a 12-fold 
increase in p21 promoter activity in LNCaP cells. Although 
the study by Wang et al. was not performed using dietary 
bioactive compounds, their results can serve to link our pre-
vious observation that UA caused a significant down-regu-
lation of both PSA and AR levels and a decrease in binding 
between AR and ARE [22] with the changes in p21 levels 
seen in the present work. Transfection of the p21 promoter 
in LNCaP cells led to an increase in its activity after UA 
incubation. Therefore, it is plausible to conclude that one 
Fig. 4  Apoptosis levels determined by flow cytometry. Repre-
sentative flow cytometer histograms displaying the cell popula-
tions. a Untreated control sample (0.12 % DMSO), b 10 μM UA 
and c 40 μM UA. d Percentage of apoptotic cells determined by 
flow cytometry. Bars represent LNCaP cells either untreated control 
(0.12 % of DMSO), or treated with increasing concentrations of UA 
for 24 h. Results represent the mean ± SE of three different experi-
ments. *p < 0.05. e Caspases 3 and 7 activation by urolithin A. Bars 
represent relative luciferase units (RLU) relative to untreated control 
after incubation with either 10 or 40 μM UA. Results represent the 
mean ± SE of three different experiments. ***p < 0.001. NS no sig-
nificant difference
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of the mechanisms by which UA exerts its effects on p21 
levels is through its transcriptional activation.
Many factors may modulate apoptosis, including growth 
factors, intracellular mediators of signal transduction and 
nuclear proteins regulating gene expression, DNA replica-
tion and cell cycle regulatory genes [38]. P21 displays a 
dual-face behavior as anti- or pro-apoptotic factor depend-
ing on the cellular localization and other stimulus [34]. ETs 
have been linked to suppressing prostate cancer cell pro-
liferation and inducing apoptosis [20, 39]. As previously 
mentioned, AR has been associated with prostate cancer 
progression; some authors suggest that a down-regulation 
of AR expression might be responsible for inducing apop-
tosis in prostate cancer cells incubated with walnut bioac-
tive compounds such as juglone, ellagic acid and urolithins 
A and B [22, 37, 40]. However, the induction of apoptosis 
by ETs has also been observed in androgen-independent 
PC3 and DU-145 prostate adenocarcinoma cells [20, 39].
We previously observed an induction of apoptosis and 
a decrease in Bcl-2 levels after incubation with urolithins 
[22]. Bcl-2 is an anti-apoptotic protein, localized to mito-
chondria, endoplasmic reticulum and the nuclear envelope, 
which interferes with the activation of caspases by prevent-
ing the release of cytochrome c [41]. Thus, in the present 
study, we measured caspases 3 and 7 activation to assess 
whether UA could promote the activity of these enzymes. 
UA caused apoptosis in a dose-dependent manner, and 
induction of caspases 3 and 7 was evident upon incubation 
with 40 µM UA, observation that to our knowledge had 
not been previously described. Naiki-Ito et al. [42] also 
reported that ellagic acid, the precursor of UA, at high con-
centrations (75–125 μM) promotes apoptosis, activates 
caspase 3 and reduces Bcl-2 protein levels in LNCaP cells. 
Interestingly, some studies assessed that cross talk between 
tumor cells and extracellular matrix proteins, when present 
in culture systems, leads to behavioral changes in tumor 
cell biology, such as increased adherence to substrates, 
increased resistance to chemotherapeutic agents and resist-
ance to apoptosis [43]. Thus, the effect of UA on tumor 
cell survival is probably multifactorial, considering that the 
extracellular protein, fibronectin (encoded by FN-1), was 
down-regulated by UA incubation and appeared as a node 
gene in our BAN.
In summary, in this work, we present novel findings on 
UA, a major polyphenol metabolite in walnuts, which mod-
ulates the expression of a wide array of genes involved in 
prostate cancer development, progression and metastasis. 
Additionally, UA exerts chemopreventive effects against 
prostate carcinogenesis in a prostate cancer cell model. 
These effects include the inhibition of cell proliferation 
and cell cycle progression through the up-regulation of 
p21 and induction of apoptosis coupled to caspases 3 and 
7 activation.
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The main objective of this thesis was to explore the effect of walnut polyphenol 
metabolites on the expression of genes related to cancer development and progression. To 
achieve this goal, first it was necessary to identify the specific polyphenolic profile of walnuts 
using a sensitive analytical approach. After such identification, a nutrigenomic approach was 
used to study the effects of the main human ellagitannin metabolites, urolithins A and B, on key 
pathways related to prostate carcinogenesis and progression.  
5.1 Identification of walnut polyphenols and their antioxidant capacity 
The identification of phenolic compounds in food matrixes is a complicated task when 
compared to supplements or drugs because of the wide variety of structures present in nature 
and the lack of standard polyphenols commercially available. Several methods have been used 
for the determination of polyphenols, such as capillary electrophoresis, gas chromatography, 
nuclear magnetic resonance, and, most commonly, high-performance liquid chromatography 
(HPLC) coupled to ultraviolet and mass spectrometry (Vallverdú-Queralt, 2010).  
Using linear ion trap quadrupole-Orbitrap-mass spectrometry (LTQ-Orbitrap-MS), 
walnuts were found to contain a highly complex mixture of gallotannins, ellagitannins, 
flavonoids and phenolic acids. Our analytic approach allowed us to tentatively identify more 
than 100 individual phenolics. Corresponding molecular formulas, their MS/MS fragments, 
mass measurement errors and retention times are shown in Table 1 of Article I. Many of these 
compounds had been previously detected in walnuts. However, the high-resolution MS 
analyses revealed the presence of other polyphenols that have never been reported in walnuts 
before. Major phenolic compounds found in walnut extracts belonged to the family of 
ellagitannins. The polyphenol content determined by the Folin-Ciocalteu method ranged from 
1,576 mg to 2,499 mg GAE per 100 g, which represents the seventh largest source of ETs in 
common foods and beverages (Vinson & Cai, 2012).  
Using ABTS+ and DPPH assays we determined average values for antioxidant capacity in 
a walnut polyphenol extract, which were 21.4 ± 2.0 mmol TE/100g and 25.7 ± 2.1 mmol 
TE/100g respectively. This was in agreement to other authors (Vinson & Cai, 2012) who also 
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reported that walnuts showed high scavenging activities, much higher than other nuts, such as 
hazelnuts, almonds or peanuts. Therefore, walnuts consolidate as an important food source of 
polyphenols with a significant antioxidant activity.  
Several studies have assessed the antioxidant capacity of ellagitannins and their impact 
on oxidative-stress and inflammation-induced disease, which are summarized in Figure D.1 
(Hseu et al., 2012; Sudheer, Muthukumaran, Devipriya, & Menon, 2007). Oxidative stress can 
be defined as an imbalance between free radical and reactive metabolites, such as reactive 
oxygen species (ROS), production and their elimination. This lack of balance can lead to cell 
damage potentially creating an impact in an organism as a whole. Over the years, epidemiologic 
and observational evidence has encouraged belief in the use of bioactive compounds with 
antioxidant potential for disease prevention (Stanner, Hughes, Kelly, & Buttriss, 2007).  
 
Figure D.1: Antioxidant activity of walnut polyphenols. 
 
 
86
Several works have explored the antioxidant effects of ellagic acid, including, the role it 
may have in the modulation of the Keap1-Nrf2 pathway, a major regulator of cytoprotective 
responses to oxidative stress. In a study by Hseu et al. the antioxidant potential of ellagic acid 
was directly correlated with the increased expression of both heme oxygenase 1 (HO-1) and 
superoxide dismutase (SOD), which was followed by the down regulation of Keap1 (kelch-like 
ECH-associated protein 1) and the increased nuclear translocation and transcriptional activation 
of Nrf2 (nuclear factor erythroid 2-related factor 2 ) in HaCaT human keratocyte cells (Hseu et 
al., 2012). In addition, ellagic acid seemed to modulate lipid peroxidation index, severity in DNA 
damage and micronuclei number in nicotine-incubated lymphocytes (Sudheer et al., 2007). 
These results further confirm the role of ellagic acid in activating a response against oxidative 
stress.   
The antioxidant capacity of ellagitannins  is particularly promising due to the increasing 
evidence from epidemiological studies and large clinical prevention trials that suggest that 
oxidative stress and DNA damage play an important role in carcinogenesis (Bell & Hawthorne, 
2008). Reactive oxygen species are generated during cell metabolism and it is thought that they 
mediate cytotoxicity by reacting with lipids, DNA and proteins to cause cell damage (Hussain, 
Hofseth, & Harris, 2003; Khan, Afaq, & Mukhtar, 2008). Moreover, research suggests that 
antioxidant levels have an inverse relationship with cancer incidence. 
Unraveling links between diet and cancer is difficult since thousands of dietary 
components are consumed each day, a typical diet may provide more than 25,000 bioactive 
food compounds. This relationship is further complicated since a single bioactive compound can 
modify multiple processes in both normal and cancerous cells. To determine the contribution of 
our diet to cancer it is necessary to understand the biological processes related to cancer 
development. Nutrigenomics is a new approach that allows us to clarify the impact of dietary 
components and nutrition in the development and progression of diseases such as cancer.  
 Considering the intricate relationship between dietary bioactive compounds and cancer, 
we worked with a prostate cancer model and focused on the interaction of urolithins A and B, 
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with carcinogenic pathways in the prostate, including, androgen receptor function, cell cycle 
and apoptosis.  
5.2 Androgen Receptor and Prostate Specific Antigen: key players in prostate carcinogenesis 
and development 
For our first nutrigenomic approach we explored the role of urolithins A and UB in the 
modulation of the androgen receptor (AR) and prostate-specific antigen (PSA) in prostate 
cancer cells. Upon androgen binding, the AR translocates to the nucleus and binds to androgen 
response elements (AREs) within the regulatory regions of target genes. The specific 
combination of cofactors that are recruited to AREs provides for tissue- and ligand-specific gene 
expression. AR has a central role in the normal growth and development of the prostate gland, 
in prostate carcinogenesis and in androgen-dependent (AD) or androgen-independent (AI) 
progression of the disease (Koochekpour, 2010).  
A staple characteristic of prostate cancer is the continual dependence on the AR for 
growth and survival. Patients with advanced prostate cancer initially benefit from androgen-
ablation therapy, which leads to a decreased level of androgens and temporary tumor 
remission due to apoptosis of androgen-sensitive tumor cells. However, relapse of disease due 
to the growth of castrate-resistant tumors is frequently observed in patients, which makes the 
conventional hormone ablation therapy ineffective (Saxena et al., 2012). AR signaling is active 
in most castrate resistant prostate cancer (CRPC) or androgen independent prostate cancer. 
PSA, an AR-dependent gene, is widely used as a marker for disease activity. PSA declines after 
initiation of hormone depletion therapy and a subsequent rise is commonly the first sign of 
disease progression. In addition, it has also been proposed that PSA may directly participate in 
prostate cancer development, potentially by promoting AR signaling, although this potential 
interaction is still highly elusive (Altuwaijri, 2012). In our study (article II), there was a clear 
repression of PSA transcription caused by urolithins A and B, as well as a decrease in PSA 
protein levels. The aforementioned decrease in PSA levels upon treatment with urolithins 
correlated with the down-regulation of AR. The decrease in PSA and AR levels after incubation 
with urolithins is in agreement with the effects reported for other phenolic compounds, such as 
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epigallocatechin gallate (EGCG), grape seed procyanidins or caffeic acid (Lin, Jiang, & Chuu, 
2012; Mantena et al., 2006; Ren, Zhang, Mitchell, Butler, & Young, 2000). In in vitro models, 
knockdown of AR results in cell death in both human and murine androgen independent-
castration resistant prostate cancer cell lines (Chen, Sawyers, & Scher, 2008). In addition, 
several authors have reported that in androgen-dependent models, AR inhibition resulted in a 
marked decrease in cell proliferation as well (Kong et al., 2011; Oh & Lee, 2011). Thus, it is 
evident that both PSA and AR play a pivotal role in prostate cancer development and 
progression and the potential cross-talk between these two genes may have important 
implications as an additional aspect of AR function, contributing to both androgen-dependent 
and independent disease, and reinforce the potential relevance of PSA as a valid molecular 
target for prostate cancer therapy (Niu et al., 2008; Saxena et al., 2012).  As such, a compound 
that can modulate the expression and activity of both AR and PSA, such as urolithins, could 
represent an important preventive approach against prostate carcinogenesis. 
5.3 The hormone-disruptive role of urolithins  
A possible manner by which urolithins could interfere with the aforementioned AR-PSA 
cross-talk is by displaying phytoestrogen-like activity.  The modulation of hormone receptors by 
dietary components, such as isoflavones, has been widely studied (Bilal, Chowdhury, Davidson, 
& Whitehead, 2014; J. N. Davis, Kucuk, & Sarkar, 2002; Signorelli & Ghidoni, 2005). Some 
authors have compared urolithins with several phytoestrogens, such as genistein, daidzein, 
resveratrol and enterolactone, and have reported that urolithins modulate endocrine pathways 
labeling them as phytoestrogens (Larrosa et al., 2006). The estrogenic and anti-estrogenic 
activity induced by urolithins has been related to their interaction with the estrogen receptor 
(ER) in MCF-7 human breast cancer cells (Larrosa et al., 2006). Larrosa (2006) and colleagues 
performed structure analyses, which revealed that both urolithin A and B exhibited structural 
characteristics that made these molecules able to bind with the α- and β-estrogen receptors. 
However, phytoestrogens like genistein, do not only interact with the estrogen receptor but 
have also been shown to interact with the androgen receptor. In a prostate cancer model  
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(LNCaP cells) 12 hour incubation with genistein caused a decrease in AR levels, as well as a 
reduction in binding of nuclear proteins to a consensus ARE (J. N. Davis et al., 2002). 
Considering all of the above, we explored whether urolithins were able to exert an 
effect over AR, similar to the effect induced by phytoestrogens. Transient transfections of PC-3 
cells with a PSA promoter construct, containing functional AREs, resulted in an 83% increase in 
promoter activity upon incubation with DHT and this induction was blocked in the presence of 
urolithins. The reduced activation of PSA, an AR-regulated promoter, could be explained by the 
decrease in the binding of nuclear proteins to a consensus ARE. In our study, urolithins’ 
modulatory actions over PSA levels were transcriptionally induced due to a direct effect on the 
PSA promoter. In this regard, the binding of nuclear proteins from urolithin A-treated cells to 
AREs was reduced by 86% in an LNCaP cell model as shown in EMSAs (Article II). An ER 
competitive binding assay performed by Larrosa and colleagues (2006) in MCF-7 cells showed 
that both urolithins had affinity for ERα and ERβ receptors, which could result in the inhibition 
of estradiol-ER binding and the subsequent binding to its response elements in the promoter 
region of target genes. These authors observed a higher binding affinity for urolithin A than for 
urolithin B, which is in agreement with our results in which a higher decrease in AR-ARE binding 
was observed upon incubation with UA when compared to UB.  Therefore, given the decrease 
in AR expression levels and decreased AR-ARE binding, it would be plausible to conclude that 
urolithins interact with AR as well, displaying a modulatory effect over steroid receptors similar 
to isoflavones and other phytoestrogens.  
In view of the aforementioned evidence it is possible to conclude that urolithins can play 
a key role in the modulation of hormone and hormone-receptor dependent diseases, such as 
breast and prostate cancers. The urolithin-hormone receptor interaction in prostate and breast 
cancer models proposed by ourselves and other authors (Larrosa et al., 2006; Sánchez-González 
et al., 2014) is summarized in Figure D.2. 
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 Figure D.2: Urolithin Interaction in hormone-dependent signaling in a) prostate and b) breast 
cancer. 
5.4 AR and p21 interaction: Influence over cell cycle progression and apoptosis 
Taking into account the results obtained in our previous study (Article II), in which 
urolithin A seemed to exert marked effects over expression and function, we decided to further 
explore the effect of this metabolite   on genome expression in LNCaP prostate 
adenocarcinoma cells. To do so, functional genomic analyses were performed obtaining lists of 
differentially expressed genes. Using a Biological Association Network (BAN) analysis, the 
relationship among the differentially expressed genes was established. These interactions 
resulted in two main gene nodes, namely CDKN1A that encodes for p21 protein, which was 
overexpressed, and FN-1 that encodes for the extracellular glycoprotein, fibronectin, which was 
underexpressed.   
Ellagic acid has been reported to induce cell cycle arrest and/or apoptosis in several 
cancer cell lines. Suggested molecular targets for ellagic acid effects are amongst others NF-kβ, 
cyclin D1, p21 and p53, all involved in regulation of cell cycle and apoptosis (Fjaeraa & Nånberg, 
2009). In view of the role that p21 has in human cancer development, its interaction with 
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ellagic acid (urolithin A precursor) and the BAN results, we validated its expression at mRNA 
and protein levels after urolithin A incubation.  A significant up-regulation of p21 was observed 
by this bioactive compound. Thus, we decided to further explore the potential effect of this 
metabolite over cell cycle progression.  P21 is a cell cycle arrest inductor that functions as both 
a sensor and an effector of multiple anti-proliferative signals. P21 inhibits cell cycle progression 
primarily through the inhibition of cyclin-dependent kinases resulting in G1 cell cycle arrest and 
a block in the transition to S phase (Piccolo & Crispi, 2012), as shown in Figure D.3. Accordingly, 
our results show that urolithin A caused an alteration in the cell cycle with an accumulation of 
cells in G1 and a reduction in S and G2.  
The role of p21 in cancer is complex, among its well-known activities, p21 mediates p53-
dependent G1 growth arrest, although recent evidence also indicates that p21 is an effector of 
multiple tumor suppressor pathways independent of p53 (Piccolo & Crispi, 2012). In CaSki 
cervical carcinoma cells, ellagic acid, the UA precursor, induced an elevation of p21 mRNA and 
protein levels, but no relevant increase level in p53 mRNA and protein levels were detected. 
These authors suggested the activation of p21 by ellagic acid could be either through a p53-
independent mechanism or by a p53-dependent mechanism that does not involve changes in 
p53 protein levels (Narayanan, Geoffroy, Willingham, Re, & Nixon, 1999). Therefore, although 
p21 activation can depend on p53, it appears that the induction of p21 by ellagitannins is not 
dependent upon p53 levels.  
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 Figure D.3. p21 and urolithin interaction in cell cycle. Adapted from (Venkateswaran & 
Klotz, 2010).  
A link between AR, PSA and p21 levels has been explored in a prostate cancer cell model 
through mechanistic studies (L. G. Wang, Ossowski, & Ferrari, 2001). Thus, it was of interest to 
study the role that urolithins might have in the possible interaction between these proteins. 
Wang et al. (2001) described that overexpression of AR was responsible for p21 silencing and 
possibly for creating resistance to apoptosis in advanced prostate cancer. AR regulation of cell 
survival or death depends on the nature of cellular context and extracellular stimuli. The pro-
survival function of AR is mediated mainly by transcriptional regulation of its target genes. By 
contrast, the pro-death function of AR can be transcription-dependent or independent. 
Although the underlying death-promoting mechanism of AR is not completely understood (Y. 
Lin, Lu, Kokontis, & Xiang, 2013), it could be related to p21 levels. In the study by Wang et al. 
(2001), a 50% reduction in AR was accompanied by a 12-fold increase in p21 promoter activity 
in LNCaP cells. This inhibition of p21 by AR levels was ARE and androgen dependent, which 
might negatively impact the sensitivity to apoptosis. Although the study by Wang et al. (2001) 
was not performed using dietary bioactive compounds, their results can serve to associate our 
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previous observation that urolithin A caused a significant down-regulation of both PSA and AR 
levels and a decrease in binding of AR to ARE (Article II) with the increase in p21 levels 
observed in our second nutrigenomic study (Article III).  
To further explore the modulation of p21 expression by urolithin A, we transfected the 
p21 promoter in LNCaP cells, and we observed an increase in promoter activity upon urolithin A 
incubation. It should be noted that unlike the inhibition of p21 by AR, which was ARE and 
androgen dependent, the induced up-regulation of p21-promoter activity was ARE-
independent (L. G. Wang et al., 2001).  Therefore, it is reasonable to conclude that urolithins 
may exert a dual effect in this AR-ARE-P21 interaction, first through AR and ARE inhibition and 
secondly, by increasing p21 levels through its transcriptional regulation.  
Taking into consideration that the expression of several genes related to cell cycle 
progression and prostate cancer cell growth were modulated by urolithins, we examined if 
these metabolites could also provoke an increase in apoptosis.  Urolithins did induce apoptosis 
in LNCaP cells, though this effect could be caused by a possible interaction in several pathways, 
first by decreasing the expression of AR target genes (such as PSA) thus inhibiting the pro-
survival role of AR and secondly by increasing p21 levels.  PSA is fundamental in the 
pathophysiology of prostate cancer. It stimulates oxidative stress in LNCaP and PC3 cells 
(Williams, Singh, Isaacs, & Denmeade, 2007), and it is also involved in  tumor invasion and 
metastasis (Webber, Waghray, & Bello, 1995). Human tumors usually express high levels of the 
anti-apoptotic protein Bcl-2 and in prostate cancer its levels correlate with high levels of PSA 
(Altuwaijri, 2012). We explored if the pronounced decrease of AR and PSA levels upon urolithin 
incubation would result in an increase in apoptosis. Urolithins did cause an increase in 
apoptotic activity in LNCaP cells. Moreover, the increase in apoptosis upon incubation with 
urolithins was correlated with a decrease in the expression of Bcl-2. Bcl-2 is localized into the 
mitochondria, endoplasmic reticulum and the nuclear envelope, and it interferes with the 
activation of caspases by preventing the release of cytochrome c (M. H. Kang & Reynolds, 
2009). Therefore, in our second nutrigenomic study (Article III), we measured caspase 3 and 7 
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activation to assess whether the decrease in Bcl-2 levels by UA could also promote the activity 
of these enzymes. An induction on caspase 3 and 7 was indeed observed after UA incubation.   
In addition, as mentioned, some authors (L. G. Wang et al., 2001) have described that 
AR overexpression was responsible for p21 silencing and possibly for creating resistance to 
apoptosis in advanced prostate cancer. The induction of apoptotic activity could be linked to 
the multi-target effect of urolithins, which caused inhibition of PSA and AR and an increase in 
p21 levels, this resulted in decreased Bcl-2 levels and increased caspase 3 and 7 activities. The 
effect of urolithins on apoptosis is summarized in Figure D.4 shown below. 
 
Figure D.4: Urolithin interaction with effectors of the apoptotic pathway. Adapted from 
(Igney & Krammer, 2002). 
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In summary, the results obtained in this work expose novel findings on the effect 
urolithins have over the expression of a wide array of genes involved in prostate cancer 
development and progression. In particular, urolithin A and urolithin B reduced PSA and AR 
levels possibly due to a decreased binding of the AR to AREs, as well as decreased levels of AR 
resulting in PSA transcription inhibition. Additionally, urolithin A exerts chemo-preventive 
effects which include the inhibition of cell proliferation and cell cycle progression through the 
up-regulation of p21, thus inhibiting cyclin dependent kinases, and the induction of apoptosis, 
coupled to Bcl-2 inhibition and caspase 3 activation. It is evident that walnut ellagitannins like 
other phytochemicals work through multiple targeted pathways. The results obtained by our 
in vitro approaches, in addition to the observed effects by other authors, warrant further 
analyses of the role that ellagitannins could have in cancer prevention using in vivo studies and 
human trials. 
Our results provide new insights in the effect that metabolites of a common dietary 
component have on molecular mechanisms involved in prostate carcinogenesis, which could in 
turn provide a foundation for developing strategies for disease prevention. The effect of dietary 
agents in cancer can be used to identify molecular therapeutic targets, and used as part of a 
chemo-preventive strategy. Dietary intervention targeting multiple pathways might, therefore, 
be an effective therapeutic approach, either alone, or in conjunction with targeted 
pharmaceutical agents.    
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6. CONCLUSIONS 
  
97
  
  
98
1. An analytical methodology for the determination of polyphenols in walnuts using HPLC-
MS has been developed, which has allowed the identification of 120 compounds, mainly 
hydrolysable and condensed tannins, flavonoids and phenolic acids. The MS analyses 
revealed the presence of eight polyphenols that have never been reported before in 
walnuts: stenophyllanin C, malabathrin A, eucalbanin A, cornusiin B, heterophylliin E, 
pterocarinin B, reginin A and alienanin B. 
 
2. The average polyphenol content in walnut extracts is 2,464 ± 22 mg GAE/ 100 g 
according to the Folin-Ciocalteau method, with an antioxidant capacity of 25.7 ± 2.1 
mmol TE/100 g by the DPPH method and 21.4 ± 2.0 mmol TE/100 g as determined by 
the ABTS+ method. Therefore, walnuts would represent the seventh largest source of 
ETs in common foods and beverages. 
3. Urolithins A and B induced a reduction of PSA (prostate specific antigen) and AR 
(androgen receptor) levels in LNCaP cells. This effect could be due to the decrease in 
binding of AR to androgen response elements (AREs), and to the down regulation  of AR 
levels resulting in the inhibition of PSA transcription.  
4. PSA transcriptional activation is modulated by urolithin A and B, through the inhibition 
of the agonist activity of dehydrotestosterone (DHT) on the PSA promoter, possibly due 
to the decreased binding of AR to the AREs present in this promoter. 
5. Urolithins A and B induced apoptosis in LNCaP cells, probably due to the down-
regulation of Bcl-2 protein levels and the increase in caspase 3 and 7 activities, caused 
specifically by urolithin A. 
6. Two main gene nodes have been identified after performing a biological association 
network (BAN) upon LNCaP cell treatment with urolithin A: CDKN1A (encoding for p21 
protein) which was overexpressed and FN-1 (encoding for the extracellular glycoprotein, 
fibronectin), which was underexpressed. 
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7. Urolithin A caused the activation of p21 promoter in LNCaP cells, possibly due to its 
interaction with the AR-ARE dimer. Furthermore urolithin A induced an alteration in the 
cell cycle with an accumulation of cells in G1 and a reduction in S and G2 phases.  
8. The effect of urolithin A on tumor cell survival is probably multifactorial, including the 
inhibition of cell proliferation and cell cycle progression through the up-regulation of 
p21, the down-regulation of fibronectin and the induction of apoptosis. 
9. In summary, it has been shown that urolithins A and B, major polyphenol metabolites of 
walnuts, modulate the expression of a wide array of genes involved in prostate cancer 
development, progression and metastasis. A diet high in ellagitannins-rich foods, such as 
walnuts, would provide a considerable intake of pedunculagin and its metabolites, 
urolithins, which could contribute to the prevention of prostate cancer. 
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View Online / Journal HomepageAttenuated total reflection infrared microspectroscopy combined with
multivariate analysis: a novel tool to study the presence of cocoa polyphenol
metabolites in urine samples
Claudia Sanchez-Gonzalez,†a Worku Nigussie,†b Ramon Estruch,cd Rosa M. Lamuela-Raventos,ad
Maria Izquierdo-Pulidoa and Silvia de Lamo-Castellvı*b
Received 29th February 2012, Accepted 21st May 2012
DOI: 10.1039/c2an35286aThe detection and quantification of polyphenols in biological samples is mainly performed by liquid
chromatography in tandem with mass spectrometry (HPLC-MS/MS). This technique requires the use
of organic solvents and needs control and maintenance of several MS/MS parameters, which makes the
method expensive and time consuming. The main objective of this study was to evaluate, for the first
time, the potential of using attenuated total reflection infrared microspectroscopy (ATR-IRMS)
coupled with multivariate analysis to detect and quantify phenolic compounds excreted in human
urine. Samples were collected from 5 healthy volunteers before and 6, 12 and 24 h after ingestion of 40 g
cocoa powder with 250 mL of water or whole milk, and stored at80 C. Each sample was centrifuged
at 5000 rpm for 10 min and at 4 C and applied onto grids of a hydrophobic membrane. Spectra were
collected in the attenuated total reflection (ATR) mode in the mid-infrared region (4000–800 cm1) and
were analyzed by a multivariate analysis technique, soft independent modeling of class analogy
(SIMCA). Spectral models showed that IR bands responsible for chemical differences among samples
were related to aromatic rings. Therefore, ATR-IRMS could be an interesting and straightforward
technique for the detection of phenolic compounds excreted in urine. Moreover, it could be a valuable
tool in studies aimed to identify biomarkers of consumption of polyphenol-rich diets.Introduction
Polyphenols commonly present in the human diet are not
necessarily the most active within the body. The reasons for this
can include low intrinsic activity, poor intestinal absorption, high
metabolism or rapid elimination.1The effects of the food matrix
on flavonoid bioavailability have not been examined in too much
detail.2 Direct interaction between flavonoids and some compo-
nents in food, such as proteins, can occur; polyphenols bind to
proteins possibly affecting their absorption. The effects of milk
as a food matrix on the excretion of cocoa epicatechin metabo-
lites in humans have been studied; Roura et al.3 reported that
while the total amount of epicatechin and its metabolites
excreted by urine did not change after consumption of cocoaaDepartment of Nutrition and Food Science- XaRTA- INSA, University of
Barcelona, Barcelona, Spain
bDepartment of Chemical Engineering, University Rovira i Virgili,
Tarragona, Spain. E-mail: silvia.delamo@urv.cat; Fax: +34 977 559
621; Tel: +34 977 559 673
cDepartment of Internal Medicine, Hospital Clinic, Institute of Biomedical
Investigation August Pi i Sunyer (IDIBAPS), University of Barcelona,
Barcelona, Spain
dCIBER 06/003 Physiopathology of obesity and nutrition (CIBEROBN)
and RETICS RD06/0045/0003, Institute of Health Carlos III, Spain
† Both authors contributed equally to this work.
This journal is ª The Royal Society of Chemistry 2012
116with water or cocoa with milk, the metabolite profile did indeed
differ. This indicates a possible influence of other diet compo-
nents on the conjugation of polyphenol metabolites. Although
total urinary excretion is roughly correlated with maximum
plasma concentrations, low values of urinary excretion could be
indicative of pronounced biliary excretion or extensive
metabolism.4
The Fourier Transform Infrared Spectrometer (FT-IR) uses
an interferometer which is capable of collecting every component
of the full electromagnetic spectrum simultaneously.5 In partic-
ular, mid infrared (MIR) spectroscopy provides unique absorp-
tion patterns for each constituent of a sample (fingerprint region)
and enables direct constituent identification at a molecular level.
Combining this technology with multivariate data analysis
results in a powerful tool to obtain and interpret chemical data.6
Specifically, attenuated total reflection (ATR) infrared micro-
spectroscopy (IRMS) has the potential for detecting subtle
compositional characteristics and differences between distinct
samples. Absorption of radiation in the MIR spectral region
provides rich information on the molecular properties of the
sample, in particular regarding composition.7 Hence, ATR
infrared microspectroscopy may be used as a diagnostic and
monitoring technique in a variety of clinical scenarios such as
alcaptonuria, Barret esophagus, esophageal adenocarcinomaAnalyst
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View Onlineand interstitial cystitis.8,9It has also been used for the detection
and discrimination of microorganisms at the serovar level.10–12
Infrared-based analysis could be advantageous over other
methods because of its much easier sample pre-treatment, short
time of analysis and its lower costs of purchase and mainte-
nance.8 The analytical applications of infrared spectroscopy have
grown greatly in the past years; this is mainly attributed to the
sensitivity of modern spectrometers combined with multivariate
analysis.8 Multivariate data analysis uses mathematical, statis-
tical and computer sciences to efficiently extract useful infor-
mation from data generated via chemical measurements.6,13
The detection and quantification of polyphenols and their
metabolites in human biological samples is mainly performed by
liquid chromatography in tandem with mass spectrometry
(HPLC-MS/MS). This technique requires the use of organic
solvents and needs control and maintenance of several MS/MS
parameters, which makes the method expensive and time
consuming. Given the versatility and simplicity of the infrared-
based methodologies, the aim of this study was to evaluate, for
the first time, the potential of using attenuated total reflection
Fourier transform infrared microspectroscopy (ATR-IRMS)
coupled with multivariate analysis as a method to detect and
quantify phenolic compounds excreted in human urine. For that
purpose, urine samples from an intervention study with cocoa
polyphenols that were already quantified by our group were
analyzed by ATR-IRMS in order to prove the validity of this
new methodology. If the IR-based methodology proves its
validity, it could be a valuable tool in studies aimed to identify
biomarkers of consumption of polyphenol-rich diets.
Experimental methods
Subjects and study design
Urine samples were obtained from 5 healthy volunteers; these
samples were obtained in a previous study14 aimed to investigate
the bioavailability of cocoa polyphenols. Samples were stored
at 80 C to maintain their integrity. Briefly, nine samples were
obtained from each volunteer after a specific test meal and time
frame. Volunteers were submitted to three interventions: milk
only (M), cocoa with milk (CM), and cocoa with water (CW) and
urine samples were taken at 6, 12 and 24 h post M, CM, and CW
intake. The description of how urine samples were obtained and
the composition of the test meals used are described in Roura
et al.14 The Institutional Review Board of the Hospital Clinic,
Barcelona, approved the study protocol and all the volunteers
gave written consent before their inclusion in the trial.
Sample preparation
Urine samples were thawed at room temperature and in darkness
for preparation. Once at room temperature, 1 mL of each urine
sample was placed in an Eppendorf tube and centrifuged at 5000
rpm for 10 min and at 4 C. After centrifugation, the resulting
pellet was removed from the samples. An aliquot of each urine
sample (22 mL) was placed by vacuum filtration onto 3 grids of
hydrophobic membrane (HGM; ISO-GRID, Neogen Corpora-
tion, Lansing, MI). Then, membranes were dried at room
temperature in dark conditions and later were stored in a desic-
cator at 4 C until being analyzed by ATR-IRMS. In totalAnalyst45 samples were prepared, 15 for each group, MC (6, 12 and
24 h), LC (6, 12 and 24 h) and M (6, 12 and 24 h).
Attenuated total reflection (ATR) infrared microspectroscopy
(IRMS)
Six spectra (two per grid) for each sample were collected using
a FT-IR microscope (Illuminate IR, Smiths detection) interfaced
with a mercury–cadmium–telluride (MCT) photoconductive
detector and equipped with a microscope with a motorized x–y
stage, 20 and 50 objectives, and slide-on attenuated total
reflection (ATR) diamond objective (Smiths detection). Spectral
data were obtained from 128 scans at 4 cm1 resolution. The
microscope was software-controlled using Wire 3.2 version
software (Renishaw plc, New Mills, Wotton-under-Edge,
Gloucestershire, GL12 8JR, United Kingdom). Spectra were
collected over the wave-number range 4000–800 cm1. Spectra
were displayed in terms of absorbance obtained by rationing the
single beam spectrum against that of the air background. The
time required to obtain one spectrum was about 40 seconds.
Multivariate analysis
Spectra were exported to the Pirouette multivariate analysis
software (version 3.1, InfoMetrix, Inc., Woodville, WA) as
‘‘.spc’’ files. The FT-IR spectral data were mean-centered,
transformed to their second derivative using a 15-point Savitzky–
Golay polynomial filter, and vector-length normalized; sample
residuals and Mahalanobis distance were used to determine
outliers.15–17 Soft independent modeling of class analogy
(SIMCA) was used to build a predictive model based on the
construction of separate PCA models for each class to describe
and model the variation.16 SIMCA class models were interpreted
based on class projections, class discriminating power and
interclass distances. Variable importance, also known as
discriminating power, was used to define the variables (wave-
numbers) that are different between samples.18 SIMCA is used
for classifying and discriminating between samples, and to
identify the component that is most responsible for the changes
between samples without using standards.
Results and discussion
Discrimination of cocoa-water polyphenol metabolites in urine
samples placed onto grids of HGM by ATR-IRMS
Typical spectra of cocoa-water polyphenol metabolites in urine
samples taken 6, 12 and 24 h after CW consumption are shown in
Fig. 1. The bands of highest proportion in the raw spectra at
approximately 1600, 1580 and 1100 cm1 were associated to –
C]C– stretching in aromatic rings19 and C–O stretching from
esters/ethers. These functional groups are common groups of
cocoa polyphenols.
Infrared spectra analysis (1800–900 cm1) using SIMCA
classification models of CW samples (data not shown) permitted
tight clustering and clear differentiation among samples. Inter-
class distances (ICDs) are Euclidian distances between centers of
clusters, and above 3.0 are considered to be significant enough to
identify 2 groups of samples as different classes.18 Values ranged
from 2.0 to 4.4 (Table 1) showing differences between theirThis journal is ª The Royal Society of Chemistry 2012
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Fig. 1 Typical attenuated total-reflection infrared spectrum of urine
samples 6, 12 and 24 h after CW consumption, using a diamond crystal
accessory in reflection mode.
Table 1 Soft independent modeling of class analogy interclass distances
of urine samples taken 6, 12 and 24 h after CW consumption. These
distances were obtained using transformed (second derivative) attenuated
total reflection microspectroscopy spectra using a diamond crystal
accessory in reflection mode and collected in the 1800–800 cm1 region
Sample CW 24 h CW 12 h CW 06 h
CW 24 h 0.0
CW 12 h 2.0 0.0
CW 06 h 4.4 3.0 0.0
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View Onlinebiochemical patterns in all classes, except between CW-12 h and
CW-24 h. These results are in agreement with Roura et al.20
These authors analyzed the content of the epicatechin metabo-
lites epicatechin-sulphate (Ec-S) and epicatechin-glucuronide
(Ec-G) in the same samples by LC-MS/MS and found that the
metabolite excretion peak occurred at the 6–12 h period, with the
lowest being at 12–24 h after consumption.Fig. 2 Soft independent modeling class analogy (SIMCA) discrimi-
nating power of transformed (second derivative, 15-point window)
attenuated total reflection infrared spectra (1800–800 cm1) using a dia-
mond crystal accessory in reflection mode of urine samples taken 6, 12
and 24 h after CW consumption. The experiments were repeated six
times.
This journal is ª The Royal Society of Chemistry 2012
118The discriminating power of SIMCA, which is a measure of
variable importance in infrared frequency,18 mainly showed 3
strong spectral bands at 1119, 1482 and 1616 cm1 (Fig. 2). The
IR band at 1119 cm1 was associated to C–O stretching of ester
groups as well as O–H vibrations of phenolic groups, and the
bands at 1482 and 1616 cm1 were linked to C–C and C]C–C
stretching of benzene ring modes and C]C vibrations of
aromatic systems, respectively.19 These results are also in agree-
ment with Roura et al.,20 since the authors reported a maximum
epicatechin metabolite excretion at the 6–12 h period and
a difference in the type of epicatechin metabolite excreted. For
example, Ec-S1 had the highest excretion at 0–6 h and the lowest
at 12–24 h. Hence, the differences among samples could be
associated with different concentrations and/or compositions of
the phenolic metabolites excreted in urine depending on the time
elapsed after consumption of CW.Discrimination of cocoa-milk polyphenol metabolites in urine
samples placed onto grids of HGM by ATR-IRMS
Typical spectra of cocoa-milk (CM) polyphenol metabolites after
6, 12 and 24 h of CM consumption are shown in Fig. 3. In this
case, another IR band at 1650 cm1 linked to amide I of protein
breakdown in milk metabolism appeared in each CM raw spec-
trum. ICDs were calculated between samples taking into account
the time passed after CM consumption, CM-06 h, CM-12 h, CM-
24 h. ICD values of CM indicated differences between the CM
urine samples according to the elapsed time after CM
consumption. ICD were in the range between 2.2 and 8.9
(Table 2) showing differences among all classes, except between
CM-06 h and CM-12 h. These differences could be related to
differences in polyphenol concentrations; these results are also in
agreement with Roura et al.3 which stated that the peak metab-
olite excretion was at the 6–12 h period, with the lowest being at
24 h after consumption. In this case, the IR bands at 1104, 1344
and 1581 cm1 were found to be very influential in the discrim-
ination power of this model. These IR bands were related to C–O
stretching of ester groups as well as O–H vibrations of phenolic
groups, C–O stretching of carboxylic acids and C–C and
C]C–C stretching of benzene ring modes19 (Fig. 4).Fig. 3 Typical attenuated total-reflection infrared spectrum of urine
samples 6, 12 and 24 h after CM consumption using a diamond crystal
accessory in reflection mode.
Analyst
Table 2 Soft independent modeling of class analogy interclass distances
of urine samples taken 6, 12 and 24 h after CM consumption. These
distances were obtained using transformed (second derivative) attenuated
total reflection spectra using a diamond crystal accessory in reflection
mode and collected in the 1800–800 cm1 region
Sample CM 24 h CM 12 h CM 06 h
CM 24 h 0.0
CM 12 h 7.5 0.0
CM 06 h 8.9 2.2 0.0
Fig. 4 Soft independent modeling class analogy (SIMCA) discrimi-
nating power of transformed (second derivative, 15-point window)
attenuated total reflection infrared spectra (1800–800 cm1) using a dia-
mond crystal accessory in reflection mode of urine samples 6, 12 and 24 h
after CM consumption.
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View OnlineDiscrimination of cocoa-milk and cocoa-water polyphenol
metabolites in urine samples placed onto grids of HGM by
ATR-IRMS
The ICDs ranged from 1.8 to 10.5 (Table 3) indicating consid-
erable variability between samples. There are significant differ-
ences in total phenolic excretion between CM and CW which
could be attributed to a variation in the concentration and
composition of polyphenols excreted. The lowest ICD was found
between CW-6 h (0–6 h) and CW-12 h (6–12 h) which, according
to Roura et al.,20 are the time frames with the highest epicatechinTable 3 Soft independent modeling of class analogy interclass distances
of urine samples taken 6, 12 and 24 h after CM and CW consumption.
These distances were obtained using transformed (second derivative)
attenuated total reflection spectra using a diamond crystal accessory in
reflection mode and collected in the 1800–800 cm1 region
Sample CM 24 h CM 12 h CM 06 h CW 24 h CW 12 h CW 06 h
CM 24 h 0.0
CM 12 h 9.5 0.0
CM 06 h 8.5 4.2 0.0
CW 24 h 9.3 5.8 2.6 0.0
CW 12 h 10.5 5.4 2.3 2.1 0.0
CW 06 h 9.9 5.4 2.4 3.4 1.8 0.0
Analystmetabolite excretion. The lowest ICD among CM samples was
found among the 6 and 12 h samples, consistent with the results
found by Roura et al.3 The highest ICDs were found between
CM-24 h and the rest of the samples, which could be due to the
effect of milk as a food matrix on the excretion profile. The CM-
06 h was the CM sample that presented the least differences when
compared to the CW samples. According to several authors3,21,22
the total polyphenol excretion is not affected by food matrix,
though milk does affect flavonoid metabolism pathways,
increasing sulfation compared with glucuronidation in the first
6 h excretion period. Discrimination power of SIMCA showed
three strong spectral bands at 1605, 1331 and 1104 cm1 (Fig. 5)
for CM (6, 12 and 24 h) and CW (6, 12 and 24 h) that were very
influential in their discrimination. The IR band at 1605 cm1 was
associated to C]C vibrations of aromatic systems, and C]O
stretching of conjugated ketone and quinones; the IR band at
1331 cm1 was linked to C–O stretching from carboxylic acids;
and the band at 1104 cm1 was related to C–O stretching of ester
groups as well as O–H vibrations of phenolic groups.19Discrimination of milk only and cocoa-milk polyphenol
metabolites in urine samples placed onto grids of HGM by
ATR-IRMS
The ICD showed significant differences between CM and M
samples (Table 4) due to the absence of phenolic groups in the M
samples. Some of the class distances obtained in the experiment
were lower than 3.
In the discrimination power of the model comparing M and
CM samples, two bands were found to be very influential, 1104
and 1581 cm1 (Fig. 6) from the phenolic components present
in CM.
The major discriminating bands found in all samples are
indicative of phenolic compounds; therefore ATR-IRMS could
be an effective method to identify polyphenols in urine. This
technique could represent a rapid and effective method to detect
biomarkers in human fluids.23,24Fig. 5 Soft independent modeling class analogy (SIMCA) discrimi-
nating power of transformed (second derivative, 15-point window)
attenuated total reflection infrared (ATR-IR) spectra (1800–800 cm1)
using a diamond crystal accessory in reflection mode, for urine samples
taken 6, 12 and 24 h after CW and CM consumption.
This journal is ª The Royal Society of Chemistry 2012
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Table 4 Soft independent modeling of class analogy interclass distances
of urine samples taken 6, 12 and 24 h after CM and M consumption.
These distances were obtained using transformed (second derivative)
attenuated total reflection spectra using a diamond crystal accessory in
reflection mode and collected in the 1900–800 cm1 region
Sample CM 24 h CM 12 h CM 06 h M 24 h M 12 h M 06 h
CM 24 h 0.0
CM 12 h 7.1 0.0
CM 06 h 8.3 2.3 0.0
M 24 h 5.7 10.3 12.6 0.0
M 12 h 7.9 3.2 2.3 11.9 0.0
M 06 h 8.2 2.9 2.2 11.6 2.3 0.0
Fig. 6 Soft independent modeling class analogy (SIMCA) discrimi-
nating power of transformed (second derivative, 15-point window)
attenuated total reflection infrared (ATR-IR) spectra (1900–800 cm1)
using a diamond crystal accessory in reflection mode, for urine samples
taken 6, 12 and 24 h after M and CM consumption.
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View OnlineConclusions
The combination of ATR-IRMS and multivariate analysis could
be a rapid, simple and available technique to detect polyphenol
metabolites in human urine after cocoa beverage (CM and CW)
consumption. FT-IR has been extensively used for food analysis
and biomedical applications, it is believed that this work
broadens its application and offers a new tool for identifying and
quantifying metabolites after the ingestion of foods with func-
tional components. The current applications of ATR-IRMS in
the food industry lay mainly in the identification of food path-
ogens, authentication of products and quality control. This is
a preliminary study to evaluate the potential of using ATR-
IRMS to identify functional components in foods, as well as their
absorption, metabolism and excretion by detecting and quanti-
fying the composition of its metabolites. Further research is
undergoing to quantify the polyphenols present in urine samples
by ATR-IRMS.
Acknowledgements
The authors would like to thank all volunteers involved in the
study, without their collaboration this project would not haveThis journal is ª The Royal Society of Chemistry 2012
120been possible. This research was supported by grants from the
Ministry of Science and Innovation (CDTI P-02-0277, PROFIT,
FIT-06000-2002-99), Generalitat de Catalunya (2009SGR724),
Nutrexpa Group (FBG-302218) and Departament Quimica of
Universitat Rovira i Virgili. CSG is supported by a CONACYT
scholarship and WN by a Universitat Rovira i Virgili
scholarship.Notes and references
1 C. S. Yang, S. Sang, J. D. Lambert and M.-J. Lee, Bioavailability
issues in studying the health effects of plant polyphenolic
compounds, Mol. Nutr. Food Res., 2008, 52, S139–S151.
2 S. Tulipani, M. Martinez Huelamo, M. Rotches Ribalta, R. Estruch,
E. Escribano Ferrer, C. Andres-Lacueva, M. Illan and
R. M. Lamuela-Raventos, Oil matrix effects on plasma exposure
and urinary excretion of phenolic compounds from tomato sauces:
evidence from a human pilot study, Food Chem., 2012, 130, 581–590.
3 E. Roura, C. Andres-Lacueva, R. Estruch,M. L.Mata,M. Izquierdo-
Pulido and R. M. Lamuela-Raventos, The effects of milk as a food
matrix for polyphenols on the excretion profile of cocoa (2)-
epicatechin metabolites in healthy human subjects, Br. J. Nutr.,
2008, 100, 846–851.
4 C. Manach, A. Scalbert, C. Morand, C. Remesy and L. Jimenez,
Polyphenols: food sources and bioavailability, Am. J. Clin. Nutr.,
2004, 79, 727–747.
5 Principles of instrumental analysis, ed. D. A. Skoog, F. J. Holler and
T. A. Nieman, Harcourt Brace College Publishers, USA, 5th edn,
1998, pp. 380–403.
6 L. Wang and B. Mizaikoff, Application of multivariate data-analysis
techniques to biomedical diagnostics based on mid-infrared
spectroscopy, Anal. Bioanal. Chem., 2008, 391, 1641–1654.
7 L. Quaroni and A. Casson, Characterization of barret esophagus and
esophageal adenocarcinoma by fourier-transform infrared
microscopy, Analyst, 2009, 134, 1240–1246.
8 A. Patrick, J. A. Markus, D. W. Swinkels, B. S. Jakobs, R. A. Wevers
and J. M. Frans Trijebls, et al. New technique for diagnosis and
monitoring of alcaptonuria: quantification of homogentistic acid in
urine with mid- infrared spectroscopy, Anal. Chim. Acta, 2001, 429,
287–292.
9 D. E. Rubio-Diaz, M. E. Pozza, J. Dimitrakov, J. P. Gilleran,
M. Giusti and J. L. Stella, et al. A candidate serum biomarker for
bladder pain syndrome/interstitial cystitis, Analyst, 2009, 134, 1133–
1137.
10 N. A. Baldauf, L. A. Rodriguez-Romo, A. E. Yousef and
L. E. Rodriguez-Saona, Differentiation of selected Salmonella
enterica serovars by fourier-transform mid-infrared spectroscopy,
Appl. Spectrosc., 2006, 60, 592–598.
11 E. M. Grasso, A. E. Yousef, S. De Lamo Castellvi and
L. E. Rodriguez-Saona, Rapid detection and differentiation of
Alicyclobacillus species in fruit juice using hydrophobic grid
membranes and attenuated total reflection infrared
microspectroscopy, J. Agric. Food Chem., 2009, 57, 10670–10674.
12 S. De Lamo-Castellvı, A. M€anning and L. E. Rodriguez-Saona,
Fourier-transform infrared spectroscopy combined with
immunomagnetic separation as a tool to discriminate Salmonella
serovars, Analyst, 2010, 135, 2987–2992.
13 D. Naumann, FT-infrared and FR-Raman spectroscopy in
biomedical research, in Infrared and Raman Spectroscopy of
Biological Materials, ed. H. U. Gremlich and B. Yan, Marcel
Dekker, USA, 2001, p. 323.
14 E. Roura, C. Andres-Lacueva, R. Estruch,M. L.Mata,M. Izquierdo-
Pulido and A. L. Waterhouse, Milk does not affect the bioavailability
of cocoa powder flavonoid in healthy human, Ann. Nutr. Metab.,
2007, 51, 493–498.
15 P. Hourant, V. Baeten, M. T. Morales, M. Meurens and R. Aparicio,
Oil and fat classification by selected bands of near-infrared
spectroscopy, Appl. Spectrosc., 2000, 54(8), 1168–1174.
16 M. Kansiz, P. Heraud, B. Wood, F. Burden, J. Beardall and
D. Mcnaughton, FTIR spectroscopy as a tool to discriminate
between cyanobacterial strains, Phytochemistry, 1999, 52, 407–417.Analyst
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ita
t d
e 
Ba
rc
el
on
a 
on
 1
9 
Ju
ne
 2
01
2
Pu
bl
ish
ed
 o
n 
23
 M
ay
 2
01
2 
on
 h
ttp
://
pu
bs
.rs
c.
or
g 
| do
i:1
0.1
039
/C2
AN
352
86A
View Online17 W. R. Hruschka, Data analysis: wavelength selection methods, in
Near-Infrared Technology in the Agricultural and Food Industries,
ed. P. Williams and K. Norris, EUA: AACC Inc, 2001, pp. 39–58.
18 W. J. Dunn and S. Wold, SIMCA pattern recognition and
classification, in Chemometric Methods in Molecular Design, ed.
H. van de Waterbeemd, EUA: VCH Publishers, 1995, pp. 179–193.
19 C. Shiroma-Kian, D. Tay, I. Manrique, M. Giusti and
L. E. Rodriguez-Saona, Improving the screening process for the
selection of potato breeding lines with enhanced polyphenolics
content, J. Agric. Food Chem., 2008, 56, 9835–9842.
20 E. Roura, M. P. Almajano, C. Andres-Lacueva, R. Estruch,
M. L. Mata and R. M. Lamuela-Raventos, Human urine:
epicatechin metabolites and antioxidant activity after cocoa
beverage intake, Free Radical Res., 2007, 41(8), 943–949.Analyst21 P. C. H. Hollman, K. H. van het Hof, L. B. M. Tijburg and
M. B. Katan, Addition of milk does not affect the absorption of
flavonols from tea in man, Free Radical Res., 2001, 34, 297–300.
22 K. H. van het Hof, G. A. A. Kivits, J. A. Westrate and
L. B. M. Tijburg, Bioavailability of catechins from tea: the effect of
milk, Eur. J. Clin. Nutr., 1998, 52, 356–359.
23 C. P. Schultz, K.-Z. Liu, J. B. Johnson and H. H. Mantsch, Study of
chronic lymphatic leukemia from infrared spectra of lymphocytes by
FT-IR spectroscopy and cluster analysis, Leuk. Res., 1998, 20, 649–
655.
24 K. Z. Liu, M. H. Shi and H. H. Mantsch, Molecular and chemical
characterization of blood cells by infrared spectroscopy: a new
optical tool in hematology, Blood Cells, Mol., Dis., 2005, 35,
404–412.This journal is ª The Royal Society of Chemistry 2012
121
                                                 
122
